







Cite this: *Nat. Prod. Rep.*, 2024, 41, 347

Harnessing the potential: advances in cyanobacterial natural product research and biotechnology†

Martin Baunach, ^{ab} Arthur Guljamow, ^a María Miguel-Gordo ^a and Elke Dittmann ^{*a}

Covering: 2000 to 2023

Cyanobacteria produce a variety of bioactive natural products that can pose a threat to humans and animals as environmental toxins, but also have potential for or inspire pharmaceutical use. As oxygenic phototrophs, cyanobacteria furthermore hold great promise for sustainable biotechnology. Yet, the necessary tools for exploiting their biotechnological potential have so far been established only for a few model strains of cyanobacteria, while large untapped biosynthetic resources are hidden in slow-growing cyanobacterial genera that are difficult to access by genetic techniques. In recent years, several approaches have been developed to circumvent the bottlenecks in cyanobacterial natural product research. Here, we summarize current progress that has been made in unlocking or characterizing cryptic metabolic pathways using integrated omics techniques, orphan gene cluster activation, use of genetic approaches in original producers, heterologous expression and chemo-enzymatic techniques. We are mainly highlighting genomic mining concepts and strategies towards high-titer production of cyanobacterial natural products from the last 10 years and discuss the need for further research developments in this field.

Received 2nd October 2023

DOI: 10.1039/d3np00045a

rscl.npr

1. Introduction
2. Estimating the hidden potential of cyanobacteria to produce natural products
3. Challenges and limitations of cyanobacterial natural products research
4. Designing a strategy for the genome-based discovery of novel cyanobacterial natural products
5. Use of multi-omics technologies for mining of cyanobacterial natural products
6. Endogenous activation of cryptic biosynthetic gene clusters in native cyanobacterial hosts
7. Use of genetic approaches for the discovery and manipulation of cyanobacterial natural products
8. Heterologous expression: *E. coli* vs. cyanobacterial hosts
9. From *in vitro* reconstitution of cyanobacterial pathways to chemo-enzymatic exploitation
10. Conclusions
11. Author contributions
12. Conflicts of interest

13. Acknowledgements
14. References

1. Introduction

Cyanobacteria are a manifold group of oxygenic phototrophic prokaryotes that are thought to be responsible for transforming the Earth's atmosphere from anoxic to oxic conditions.¹ However, cyanobacteria are also notorious for producing environmental toxins and are repeatedly associated with poisoning in humans and animals.² It was primarily the toxins that attracted the interest of natural product researchers to cyanobacteria early on. Attention was initially focused on freshwater genera such as *Microcystis*, which form macroscopically visible colonies and can form dense surface blooms in eutrophic lakes (Fig. 1A and B).³ *Microcystis* is now recognized as one of the most widespread producers of the potent hepatotoxin microcystin (1).⁴ Another threat in freshwater lakes comes from the production of neurotoxins such as saxitoxin (2) and anatoxin by different species of filamentous cyanobacteria (Fig. 1E).² Cyanobacteria were also associated with severe skin irritations after swimming in marine environments. Such symptoms can be caused by mat-forming cyanobacteria such as *Moorena* in coastal habitats and were connected to the production of the

^aUniversity of Potsdam, Institute of Biochemistry and Biology, Karl-Liebknecht-Str. 24/25, 14476 Potsdam, Germany. E-mail: editt@uni-potsdam.de

^bUniversity of Bonn, Institute of Pharmaceutical Biology, Nussallee 6, 53115 Bonn, Germany

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3np00045a>



dermatotoxins lyngbyatoxin and aplysiatoxin.⁵ The adverse effects on humans and animals have led to extensive bioactivity-guided screening programs of cyanobacteria that also included cyanobacteria of terrestrial origin in addition to freshwater and marine strains.⁶ Of particular importance in terrestrial habitats is the filamentous genus *Nostoc*, which can fix nitrogen and live both freely in the soil and in association with diverse plant hosts, such as cycads, where the cyanobacteria reside in coral-oid roots (Fig. 1C and D).^{7,8}

Widespread interest in cyanobacteria has increasingly revealed the structural uniqueness of cyanobacterial natural products and their versatile bioactive potential.^{9–11} Notably, cyanobacteria produce a number of highly active cytotoxic compounds that have attracted pharmaceutical interest such as dolastatins (3) and cryptophycins (4).^{12,13} There are also cyanobacterial natural products with antibiotic properties, such as

the hapalindole family of compounds (5).¹⁴ The significant bioactive potential of cyanobacteria has been confirmed by genome sequencing programs over the past two decades, and furthermore, a large untapped biosynthetic potential has been revealed.^{15,16} In particular, cyanobacterial genomes frequently contain biosynthetic gene clusters (BGCs) encoding non-ribosomal peptide synthetases (NRPS), polyketide synthases (PKS) or hybrids thereof, as well as ribosomally produced and posttranslationally modified peptide (RiPPs) and terpene biosynthetic pathways. Despite all progress made in assigning of BGCs to known families of cyanobacterial natural products (detailed in previous reviews^{9–11,17}), to date 80% or more of BGCs are still orphan.

Besides being a rich source of unique natural products; cyanobacteria also hold great promise for sustainable production of chemical compounds.¹⁸ Cyanobacterial biotechnology



Martin Baunach

Martin Baunach studied biochemistry at the University of Jena and obtained his PhD at the Leibniz Institute for Natural Product Research and Infection Biology (Hans Knöll Institute) under the supervision of Christian Hertweck. As a postdoctoral fellow, he joined Elke Dittmann's group at the University of Potsdam, where he became fascinated by the biology and chemistry of cyanobacteria. Since 2022 he is Assistant

Professor of Pharmaceutical Biology at the University of Bonn. His research interests include all aspects of microbial natural products.



Arthur Guljamow

Cyanobacteria have been central to Arthur Guljamow's interests from the early beginnings of his scientific career. As a biologist he is intrigued by the unique physiology and metabolism of these oxygenic phototrophs. After his PhD work at Humboldt University in Berlin he joined Dario Leister's group of Molecular Botany at Ludwig-Maximilians-University in Munich where he focused on cyanobacterial Synthetic Biology

and Green Biotechnology. As a member of Elke Dittmann's group in Potsdam he contributes his expertise in physiology and genetic engineering of Cyanobacteria to unravel the many mysteries surrounding cyanobacterial natural products.



Maria Miguel-Gordo

María Miguel-Gordo earned her MSc in Pharmacy and Chemistry of Natural Products from the University of Salamanca, Spain, and the Polytechnic Institute of Bragança, Portugal. Her academic journey continued with a PhD in Chemistry at NUI Galway, Ireland, where she explored the chemodiversity of marine sponges sourced from the Pacific Ocean. Driven by her interests in natural products chemistry, biosynthetic path-

ways, and functional roles of secondary metabolites, she joined Elke Dittmann's group at the University of Potsdam, Germany, as a Postdoctoral researcher. In this role, she is currently focused on the application of multi-omics to uncover the biosynthesis of cyanobacteria.



Elke Dittmann

Elke Dittmann has been fascinated by cyanobacterial natural products for many years and is interested in their biological roles, biosynthesis, regulation and evolution. She holds a degree in biochemistry and a PhD in molecular biology from the Humboldt University of Berlin and carried out a post-doctoral research with Brett A. Neilan at the University of New South Wales in Sydney, Australia. After a position as junior

professor at the Humboldt University of Berlin, she moved to the University of Potsdam as Professor of Microbiology. Her research aims to develop concepts for the genomic mining and exploitation of natural products from cyanobacteria.






Fig. 1 Macroscopic and microscopic images of cyanobacteria from different habitats and selected natural products from cyanobacteria. (A) *Microcystis* bloom in Lake Wannsee in Berlin, Germany. (B) Enrichment of diverse cyanobacterial species including *Microcystis* sp. (M), *Aphanizomenon* sp. (Aph) and *Anabaena* sp. (An) in a net sample of Lake Zernsee in Potsdam, Germany (C), cross section through a coralloid root taken from a *Cycas revoluta* plant from the Botanical Garden in Potsdam, Germany and (D) isolated cyanobacteria of the genus *Nostoc* from the same root sample. (E) Chemical structures of selected cyanobacterial environmental toxins and pharmaceutically relevant compounds. The producing genera and the common habitat are indicated. Subfigure B was kindly provided by Rebecca Große. Scale bar: 1 mm.

has long outgrown its infancy. An increasing number of companies are cultivating cyanobacteria at large scale as food supplements, cosmetics or fertilizers or develop them as chassis for the production of biopolymers, biofuels and pigments.¹⁹ The autotrophic metabolism of cyanobacteria enables the production of organic chemicals using only sunlight, CO₂ and minerals. Production through green biotechnology is CO₂ neutral or even CO₂ negative and meets the aim of establishing a climate-neutral circular bioeconomy.¹⁹ Accordingly, there are extensive efforts to further develop methods of synthetic biology for cyanobacteria and to expand the product range. Currently, synthetic biology and biotechnology of cyanobacteria is focused on unicellular model strains of the genera *Synechococcus* and *Synechocystis* and on the edible genus *Spirulina*.²⁰ Considering both the richness in untapped BGCs with great pharmaceutical and biosynthetic value and the possibility for exploitation by sustainable biotechnology, cyanobacteria could become a mainstay of microbial natural product research.

Yet, both the assignment of unknown BGCs to unknown metabolites and the high-titer production of complex specialized metabolites of cyanobacterial origin in cyanobacterial hosts are not well advanced. From our microbiological perspective, similar obstacles are currently limiting both the genomic mining of new compound families in cyanobacteria and their high-titer production in cyanobacteria. Understanding the bottlenecks that limit growth of cyanobacteria, production of specialized metabolites as well as amenability to genetic manipulation can potentially advance both the field of natural product discovery as well as provide avenues for the production of specialized compounds or new-to-nature

compounds in cyanobacteria. In the present review, we have therefore set ourselves the goal not only to compile the current state of knowledge on method development of natural product research in cyanobacteria, but also to identify gaps that should be addressed for efficient natural product exploitation.

2. Estimating the hidden potential of cyanobacteria to produce natural products

As in many bacterial groups, cyanobacteria include highly adapted specialists that thrive primarily in habitats with stable conditions as well as versatile adapted generalists that can exhibit a highly variable lifestyle.²¹ The range extends from unicellular minimalists to multicellular organisms with pronounced cellular differentiation and genome sizes between 1 and 12 Mbp.²¹ Genome-streamlined specialists are especially abundant in marine habitats, but versatile multicellular genera thrive in different niches of terrestrial, freshwater as well as marine environments. A comparative analysis has recently shown that gene family expansion is a common strategy in cyanobacteria and is particularly observed in terrestrial cyanobacteria which are exposed to a fluctuating environment and also reach the largest genome sizes. Hundreds of cyanobacterial genes were found to be highly habitat specific.²¹ Unsurprisingly, this fact is also reflected in the potential for natural product biosynthesis.

Following the CyanoGEBa initiative that aimed to improve the sequence coverage by sequencing diverse axenic strains of the well curated Pasteur Culture Collection of Cyanobacteria



(PCC),¹⁵ Gugger and coworkers carried out a phylum-wide analysis of the presence of NRPS and PKS gene clusters. This analysis revealed a burst of these genes in late branching lineages of cyanobacteria which are dominated by multicellular genera of marine, freshwater and terrestrial origin. Moreover, the study indicated that 80% or more of the NRPS and PKS BGCs were still not assigned to their products.¹⁶ A comprehensive analysis covering all types of BGCs identified by AntiSMASH (in particular NRPS, PKS, RiPPs and terpenes)²² was recently presented by Ziemert, Medema and coworkers, who created a compendium for the potential to produce specialized metabolites for bacterial genomes and metagenomes.²³ This involved adapting the BiG-SLICE software tool,²⁴ which subdivides unique BGCs into distinguishable gene cluster families (GCFs) that were adapted to the hierarchical clustering of compounds in the NPAtlas database.²⁵ The study revealed a significant dissimilarity of GCFs at the genus level rather than species level as well a correlation with the habitats.²³ To reliably rank the biosynthetic diversity among phyla, the study applied a common phylogenetic metric, relative evolutionary divergence (RED) groups, which were roughly consistent with the genus range across phyla.²⁶ For cyanobacteria, 536 genomes were included in the comparative part of the study and classified into 142 RED groups. For these genomes, 1,867 actual unique GCFs were predicted ranking cyanobacteria fifth behind actinobacteria, proteobacteria, firmicutes and bacteroidota.²³ Since the necessary sequence depth to cover all cyanobacterial GCFs is far from being reached, the authors also estimated the diversity potential of GCFs that could be reached if the sequencing was saturated. Thereby, a diversity of approximately 5,000 unique GCFs was indicated for cyanobacteria in total. Both the actual and the estimated GCF diversity are distributed very differently among phyla. Fig. 2 zooms into the 30 richest RED groups of cyanobacteria, which are responsible for 87% of the cyanobacterial actual GCF diversity. Seventeen of the groups are assigned to the order *Nostocales* comprising a diversity of different genera including amongst others *Nostoc*, *Fischerella*, *Calothrix*, *Scytonema*, *Nodularia* and *Cylindrospermopsis* while in the orders Chroococcales, Oscillatoriales and Synechococcales rather single genera such as *Microcystis*, *Moorena*, *Planktothrix* and *Leptolyngbya*, stand out, respectively (Fig. 2). However, there is a bias with regard to the number of genomes representing different RED groups. Thus, at the present time, one can read a trend rather than make a ranking among phyla. Nevertheless, it is possible to draw valuable conclusions from the analysis. (1) The known prolific natural product producing genera such as *Nostoc*, *Microcystis* and *Moorena* are indeed among the bacterial groups with the greatest actual and estimated genomic potential. (2) The current 144 entries of characterized BGCs of cyanobacteria included in the MIBiG database (ref. 27, as of August 2023) occupy only a small fraction of the actual 1,867 GCFs identified for cyanobacteria. Although it must be assumed that the MIBiG database does not cover all characterized BGCs, there is a large untapped potential for cyanobacteria to produce natural products which can be estimated at about 90%. The order *Nostocales* shows by far the largest hidden potential to produce natural products. (3) For some genera or RED groups,

a significant number of GCFs is matched by only a few entries in the NPAtlas database.²⁵ This is particularly true for the genus *Pleurocapsa* solely representing the poorly investigated order Pleurocapsales for which there is only one entry in NPAtlas. The analysis by Ziemert, Medema and coworkers also revealed a low sequence coverage for this genus.²³ There are other rich genera for which there are few entries in the NPAtlas database (<15).²⁵ These include, for example, the genus *Calothrix*. This is particularly interesting because three of the five largest cyanobacterial genomes sequenced to date were assigned to the genus *Calothrix*.²¹ Further notable genera include *Cylindrospermopsis* and *Crocospheara* which are not intensively investigated yet. (4) Members of the orders Synechococcales and Spirulinales have only a small number of predicted GCFs. Although six Synechococcales RED groups made it to the list of most productive groups, they represent only a small subgroup of a much larger phylum; the majority of all *Prochlorococcus* and *Synechococcus* strains barely have predictable GCFs.²³ Also, for the genus *Synechocystis*, to which the model strain *Synechocystis* sp. PCC 6803 belongs, a total of only 8 GCFs are predicted. From this analysis, one can conclude that unicellular cyanobacteria rarely have a great potential for natural product biosynthesis (except colony formers such as *Microcystis* or *Crocospheara*). The situation is similar for the filamentous order Spirulinales, for which there is also only one entry in NPAtlas.²⁵ One can therefore also state that the strains currently used for cyanobacterial synthetic biology and biotechnology generally have a very low natural product biosynthetic potential. We will discuss this fact again later when we talk about available tools and growth of cyanobacteria.

While the integration of different databases such as the MiBIG database and NPAtlas is very useful,^{25,27} some of the conclusions that can be drawn when comparing the GCF analysis and the NPAtlas database must be viewed with caution. Many of the entries in NPAtlas go back to older studies. Cyanobacterial taxonomy has undergone many changes since then, and many genus names were created only in the course of more detailed 16S rRNA analysis and taxon refinement.²⁸ It is therefore unsurprising that certain genus names with high GCF potential rarely appear in NPAtlas. These include, for example, the genera *Aulosira*, *Trichormus* or *Dolichospermum*, which were more commonly used recently and previously classified under *Anabaena* or *Nostoc*.^{28–30} Well-known examples of name changes in the field of natural products also include the change of the species name *Lyngbya majuscula*, first in *Moorea producens* and later to *Moorena producens*^{31,32} and *Oscillatoria agardhii* to *Planktothrix agardhii*.³³ While taxon refinement is a general trend in modern microbiology, the situation is even more complicated in cyanobacteria. Longer than for other bacterial phyla, cyanobacterial taxonomy was largely based on morphology and reference strains were described according to the rules of the International Code of Botanical Nomenclature (ICBN) rather than the International Code of Nomenclature of Prokaryotes (ICNP).³⁴ The problem of the morphology-based phylogeny is at least two-fold. Not all morphological features used for classification correspond to the molecular phylogenetic classifications and the morphological classifications






Fig. 2 Number of distinct biosynthetic gene cluster families (GCFs) in different phylogenetic groups of cyanobacteria and number of cyanobacterial entries in the Natural Product Atlas. (A) Number of GCFs in standardized relative evolutionary divergence (RED) groups as defined in Gavrilidou *et al.*²³ RED groups correspond to single genera of cyanobacteria or may include strains of multiple genera of cyanobacteria (as indicated in parentheses). The number of genomes used for the analysis in individual RED groups is given in parentheses next to the GCF number. Data were adapted from Gavrilidou *et al.*²³ (B) Number of cyanobacterial chemical entities in different orders and genera of cyanobacteria according to Natural Product Atlas (ref. 25 as of August 2023). The color coding corresponds to the assignment of the genera or RED groups to the orders Nostocales (orange), Chroococcales (blue) Oscillatoriales (yellow), Synechococcales (green) and Pleurocapsales (purple).

require a specific expertise which is not always available. Therefore, one must also assume false annotations and genus names may occur several times in different polyphyletic groups.²⁸ Even if the genus and species name chaos is gradually being resolved by careful polyphasic analyses that consider both morphology and molecular phylogeny and increasing sequencing depth, the problem is still reflected in the databases. The genus name is therefore often not a useful identifier in the cyanobacterial phylum.

3. Challenges and limitations of cyanobacterial natural products research

There are currently three main reasons that complicate natural product research in cyanobacteria. The first of these is the comparably poor growth of the autotrophic bacteria, which slows down all approaches in both basic research and applied biotechnology.³⁵ Another obstacle is the fact that heterotrophic bacteria associate themselves very stably to the carbon- and often also nitrogen-fixing cyanobacteria.^{36–38} Even though diverse protocols for cyanobacterial axenization exist, cyanobacteria are frequently kept as xenic isolates even in strain collections.^{37,38} This makes isolation of the bacteria very laborious and exposes research work and biotechnology to a high risk of contamination. Last but not least, an efficient

exploitation of cyanobacterial natural products and their biosyntheses is hindered by the frequent lack of accessibility for genetic manipulations.³⁹ This limits the characterization of biosynthetic pathways in the cyanobacteria themselves and the development of production strains. Some of the challenges are general to work with cyanobacteria, and many are particularly applicable to work with prolific natural product producers. We highlighted in the previous section that these are primarily multicellular strains, such as those in the genera *Nostoc*, *Moorena*, *Fischerella*, or *Microcystis*. These genera are characterized by a massive mucus layer and form a particularly close association with heterotrophic bacteria. The pronounced sheath makes not only axenic isolation but also genetic manipulation a particular challenge.

The growth rates of cyanobacteria differ considerably. While some model strains achieve doubling times between 2–6 hours under ideal conditions, many cyanobacteria divide only about once a day even under optimal conditions.³⁵ The first group mainly includes model strains of the genera *Synechococcus* and *Synechocystis*, with the strain *Synechococcus elongatus* UTEX 2973 being the frontrunner with a doubling time of 2 h under autotrophic conditions.⁴⁰ The latter group, on the other hand, includes genera with high natural product potential such as *Nostoc* or *Microcystis*.⁴¹ Thus, all work with these non-model genera is automatically associated with a high time expenditure. The growth of cyanobacteria depends mainly on



photosynthetic rates and CO₂ availability.³⁵ Photosynthetic rates, in turn, depend on light intensities, whereby cyanobacteria stand in their own way because they attenuate light through shading at higher cell densities. Higher light intensities again trigger photoinhibition, so there is limited scope for cyanobacteria to grow.³⁵ CO₂ concentrations cannot be increased arbitrarily either, because this decreases the pH in the medium. A simple way to increase the biomass production of cyanobacteria, which has proven particularly useful for natural product producers, is the so-called high-density cultivation (HDC). The technology was developed by the CellDEG company in Berlin and enables bubble-free gas exchange and turbulent mixing on a vibrating membrane. HDC minimizes photobleaching and photoinhibition leading to a high quantum yield even at high light intensities.⁴² For the model strain *Nostoc punctiforme* PCC 73102, not only much higher cell densities and biomass accumulation is achieved by HDC, but growth rates are also increased by a factor of 2–3.⁴³ Some of the natural product-rich genera can accumulate biomass very efficiently in nature. This is especially true for bloom-forming genera such as *Microcystis*, *Planktothrix*, *Nodularia* or *Dolichospermum*,⁴ but also for mat-formers such as *Moorena* and *Symploca*.^{31,44} A considerable number of cyanobacterial natural products have been isolated directly from field material, such as from *Microcystis*⁴⁵ or *Symploca*,⁴⁶ which are relatively easy to harvest. However, many downstream applications and a detailed BGC characterization are more difficult without cultivation.

Looking at the success of cyanobacteria in nature, there is obviously quite some potential for optimizing growth rates even for genera like *Microcystis* or *Nostoc*. However, this also requires an understanding of the bottlenecks that currently impede rapid growth in the laboratory. The heterotrophic microbiome of bacteria seems to play a key role in this context. For *Microcystis* in particular, there are studies showing that the relationship with heterotrophic bacteria is predominantly growth-promoting for the cyanobacteria, although the reasons are not well understood.⁴⁷ As mentioned above, heterotrophic bacteria are an obstacle to reproducible research and biotechnology. Yet, one could certainly harness the contribution of heterotrophic bacteria to cyanobacterial growth by supplementing axenic bacterial isolates with selected heterotrophic partners in synthetic communities. This is an emerging trend in the synthetic biology of cyanobacteria,⁴⁸ which could also have a lasting impact on the development of model production strains in natural product research.

Not all questions to be addressed in cyanobacterial natural product research necessarily require axenic isolates. The assignment of BGCs to natural products or *vice versa* does not necessarily have to be carried out with pure strains. The analysis of metagenomes has now progressed to the point where assignment to cyanobacterial genomes is reliably possible.³⁷ The assignment of biosynthetic pathways is in any case usually supported by further analyses, such as feeding studies or *in vitro* characterizations of enzymes. Despite the progress in purifying strains some genera of cyanobacteria are only accessible as axenic isolates. However, this does not diminish the value of axenic cultures, especially for non-model genera such as

Microcystis or *Nostoc*. Physiological and molecular biological experiments are dependent on axenic strains. Genetic manipulations are currently limited to a few strains. This problem has changed little in recent years. However, there has been a breakthrough in the biotechnologically important genus *Spirulina*, which is being cultivated at large scale but was not amenable to genetic manipulation. Recently, *Spirulina* has been efficiently established as a chassis for high-titer expression of therapeutic proteins. It was shown that *Spirulina* could only be manipulated in coculture with selected heterotrophic bacteria.⁴⁹ These findings may point the way forward for cyanobacterial natural product producers. Again, synthetic consortia could provide a solution. Doudna and colleagues have recently also demonstrated the possibility of species- and site-specific genome editing in complex bacterial communities *via* an RNA-guided CRISPR-Cas transposase (DART) system.⁵⁰ Although this technique has not been applied to cyanobacteria yet, it opens up new possibilities for the analysis of cyanobacterial consortia. We will revisit the issue of genetic manipulation later when we discuss in detail the use of genetic methods in the natural products field.

4. Designing a strategy for the genome-based discovery of novel cyanobacterial natural products

Many of the well-studied cyanobacterial species produce a limited number of specialized metabolites largely constitutively. Individual strains of the genus *Microcystis*, for example, commonly produce 2–5 classes of peptides, such as microcystins, cyanopeptolins, aeruginosins, anabaenopeptins, microginins, aeruginoguanidins, cyanobactins, and microviridins, in different combinations.⁵¹ Terrestrial symbiotic bacteria of the genus *Nostoc* also produce various families of peptides, including microcystins, aeruginosins, anabaenopeptins, and also nostopeptolides and nostocyclopeptides.⁸ These constitutively produced peptides are relatively easy to detect and are recurrently discovered. Numerous analogues of many of these compound families have been described and their initial description was usually by bioactivity-based purification (Fig. S1†).²⁵ In contrast, genome-based discovery of entirely new classes of cyanobacterial natural products requires the development of rational strategies for assigning metabolites to their BGCs, characterizing BGCs, and optimizing production titers.

In addition to an appropriate dereplication strategy for the known natural product classes, it is central to this effort to understand the reasons for the lack of assignment of compounds to orphan BGCs. In the search for causes, the continuously improved bioinformatic analysis of BGCs, especially by the AntiSMASH platform,²² is a very good basis, not only because BGCs are reliably predicted, but also because structural prediction is often possible through increasing insights into the role and specificity of enzymes.

A first step into developing a strategy for the discovery of new natural products is often transcriptional analysis.⁵² This






Fig. 3 Workflow for the development of experimental strategies towards the genome-based discovery of cyanobacterial metabolites, characterization of their biosynthesis, and high-titer production of bioactive compounds.

analysis can reveal whether cyanobacterial BGCs are silent and whether production of the corresponding metabolites can be expected under the given cultivation conditions. These findings can be paired with metabolomic studies. For the model strain *N. punctiforme* PCC 73102, it was shown that the majority of cryptic BGCs are actively transcribed, but only at very low levels.⁵³ Moreover, a transcriptional reporter analysis revealed that expression is often restricted to a few cells within the multicellular consortium.⁵³ Low levels of transcription in turn can be assumed to lead to low metabolite production levels. Based on these findings, one can consider different methodological options and develop workflows depending on the purpose of the analysis and properties of the investigated strains (Fig. 3). (1) Can transcription of BGCs and metabolite production be stimulated in the cyanobacterial strains? In principle, different abiotic and biotic conditions can be tested randomly. This approach is commonly designated as OSMAC approach (one strain – many compounds).⁵⁴ However, a more rational approach can also be taken, for example if there are regulatory factors or transport proteins that have already been characterized in other bacteria in the vicinity of BGCs and when a functional hypothesis can be deduced. (2) Is the strain amenable to genetic manipulation? Accessibility to genetic engineering offers many possibilities such as overexpression of regulatory components and characterization of biosynthetic intermediates and tailoring enzymes. (3) Is the purpose of the analysis primarily to characterize a BGC and develop a production strategy? Then, heterologous expression is an increasingly successful choice for cyanobacterial BGCs.⁵⁵ It depends on the ultimate goal which production hosts are suitable, with the

focus being especially on *E. coli* and well manipulable model strains of cyanobacteria. (4) Are biochemical reactions and precursors for the assembly of compounds well predictable? Then *in vitro* reconstitution offers an elegant way to characterize BGCs or even to produce bioactive compounds. All methodological approaches are associated with individual challenges. Very often, different methodological options are being combined. Combining alternative technologies is particularly important because of the named bottlenecks in cyanobacterial natural product research, their slow growth, frequent contamination with heterotrophic bacteria, and poor accessibility for genetic manipulation. Hereafter, we will dissect the progress in the different methodological fields.

5. Use of multi-omics technologies for mining of cyanobacterial natural products

The -omics revolution in the last decades has significantly changed the cyanobacterial natural products research. Similar to other microbial phyla, natural product discovery is gradually shifting from the traditional bioactivity-guided screening strategies to genome mining and metabolomic approaches, or a combination of both for better dereplication and prioritisation. Additionally, the advances in transcriptomics and proteomics are key to facilitating the link between the BGCs and the specialized metabolites.^{56,57} Workflows on genomic-metabolomics have been reviewed recently, all having their challenges and limitations, but also numerous benefits, leaving the decision of the strategy of choice to the researcher.^{58–60} So



far, genome mining and untargeted metabolomics, the most common metabolomics in secondary metabolites discovery, rely on the comparison of experimental data with databases to identify known/unknown BGCs or molecules, respectively. Therefore, the creation of publicly available databases of genomic data, chemical structures and their properties, spectral libraries, and metabolomics is essential for the progress in dereplication analysis, but also for biological and taxonomic studies. Databases for microbial research have been reviewed until 2020 (ref. 61) and are continuously expanding as exemplified by the construction of specific repositories like CyanoMetDB,⁶² dedicated to cyanobacterial toxins and secondary metabolites and its incorporation into the NPAtlas database²⁵ and the recently created LOTUS collaborative database of natural products.⁶³ In addition, new initiatives are arising under the necessity to link the emergent multi-omics data, like the Paired Omics Data Platform (PoDP) whose aim is linking the genomic and metabolomic data deposited in public repositories.⁶⁴

In this context, a number of studies on cyanobacteria have already implemented advanced genomics-metabolomics strategies to dig into the genomes, prioritise and connect the biosynthetic machineries with their products.¹¹⁻¹⁷ Genome-guided methodologies can expand chemical families by interrogating the genome in different strains and searching for variants of known BGCs or enzymes, which coupled with mass spectrometry (MS)-based strategies, allows the assignment of BGCs to products. For example, new cyanobactin linear peptides were found after genome mining of 126 cyanobacterial strains. Using BLAST searches for the signature proteases PatA and PatG, 31 putative cyanobactin BGCs were identified. A closer inspection of these sequences predicted the presence of cyanobactins containing not only the characteristic thiazoles but also methylation(s) and prenylation(s) as further post-translational modifications in *Microcystis aeruginosa* PCC 9432 and *Oscillatoria nigro-viridis* PCC7112. The liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis identified peptides with these key features and guided the discovery of aeruginosamide B (Fig. 4, 6) and C and viridisamide A.⁶⁵ The pairing between particular enzymatic domains within BGCs and MS or NMR signatures is an effective tool that can work in both ways, finding the characteristic metabolites using BGC prediction in complex extracts or deorphanizing BGCs with known distinctive compounds. For instance, halogenases can be linked with the MS isotopic patterns of halogens as exemplified in the discovery of columbamides A, B and C in *Moorena bouillonii* PNG. A paired genomic and metabolomic comparison of three *Moorena* strains correlated a novel BGC in *M. bouillonii* that encoded cryptic halogenase domains with two clusters of halogenated compounds found exclusively in *M. bouillonii* using Global Natural Products Social Molecular Networking (GNPS) analysis.^{66,67} Compounds of these clusters were selected for isolation leading to the structure elucidation of the columbamides and allowing assignment of the previously unknown *col* BGC.⁶⁸

The capacity to identify the isotopic patterns can be further exploited by stable isotope-labelled supplementation

experiments based on the BGC features. Applying a lipid-version of the genomisotopic approach, new fatty acids (FA)-derived compounds were discovered using supplementation experiments with deuterated FA and comparative metabolomics. After proving the absence of a beta-oxidation pathway in cyanobacteria, which supports the prevalence of FA-derived compounds, supplementation experiments were designed to detect labelled metabolites in different cyanobacterial strains containing FA-incorporating enzymes. Comparative metabolomics between supplemented and non-supplemented cultures was performed by LC-HRESIMS and combined with data processing in MZmine,⁶⁹ whose modules allow filtering the peak list, for example by adducts. Feature-based molecular networking using GNPS and MS-guided isolation focusing on unknown features led to the identification of new hapalosin analogues in *Fischerella* sp. and the nocuolactylates A (Fig. 4, 7) and B in *Nodularia* sp.⁷⁰ In another experiment, labelling with stable ¹⁵N was performed in *Nostoc* sp. UIC 10630 to correlate BGCs with their metabolites by pairing the prediction of nitrogen atoms according to the amino acid specificity of adenylation domains with the number of nitrogen atoms identified by comparative metabolomics between labelled and unlabelled experiments. This approach was able to deorphanize three of the six BGCs predicted to contain nitrogen in their products, a new anabaenopeptin analogue, a new compound named nostopyrrolidonamide and also the known aeruginosin 865 whose cluster was formerly unidentified.⁷¹

As can be seen, retro-biosynthetic strategies can be useful to connect known compounds with their BGCs provided that the order of BGC modules shows collinearity with the order of building blocks in the compounds, as is common in type I PKS, NRPS and hybrid PKS-NRPS pathways. This tactic was applied to assign the biosynthetic pathway of aeruginoguanidines (AGDs), and then the microguanidines (MGDs) that were co-assigned to the same BGC in *Microcystis* strains.⁵¹ According to the structural features of AGD the predicted pathway was expected to involve an NRPS with specificity for L-arginine and tailoring enzymes such as a prenyltransferase and a sulfatase/sulfotransferase. A candidate BGC fulfilling the expected features was found in the AGD-producing strain *M. aeruginosa* NIES-98 and screened in other public *Microcystis* genomes. Subsequent analysis of metabolomes using LC-MS/MS revealed the presence of AGD in eleven strains of *Microcystis*. Molecular networking analysis expanded the AGD compound family with new variants AGD-98A (Fig. 4, 8), AGD-98B and AGD-98D, but unexpectedly also revealed the presence of another cluster in the same strains, comprising shorter MGD variants. Isolation and structure elucidation of the MGD metabolites, revealed new variants and new intermediates, the microguanidines amides MGA-771, and MGA-787. Analysis of the presence/absence of the compounds and genes in the different strains by a phylogenetic approach uncovered the unprecedented biosynthetic versatility of the AGD/MGD/MGA pathway and showed that the production was mutually exclusive with microcystin.⁵¹

(Meta)-genomics has boosted the exploration of cyanobionts with several successful examples linking biosynthesis and chemistry, as it can be seen in the recent review of D'Agostino.¹¹






Fig. 4 Examples of integrative genomics-metabolomics strategies to link and identify cyanobacterial BGCs and the corresponding metabolites by pairing biosynthetic and structural features, isotopic labelling, or using a retrobiosynthetic approach.

The development of these technologies also facilitates the study of collections of microorganisms, rather than single organisms, and computational networking approaches enable the visualization and data analysis of large datasets. Following a phylogenetics-guided multi-omics study, the genome and metabolome of 24 tropical filamentous cyanobacteria were compared to evaluate the natural product potential and to prioritise strains.⁷² The sequence similarity networking of BGCs was created from the meta-genomic assemblies of the environmental cyanobacteria using antiSMASH,²² BIG-SCAPE⁷³ and the MIBIG²⁷ database to assign the GCFs. The BGC similarity network was integrated with a classical GNPS molecular networking generated using LC-MS/MS and *in silico* annotation tools such as Network Annotation Propagation,⁷⁴ DEREPLICATOR+,⁷⁵ and MolNetEnhancer⁷⁶ for the chemical classification. Interestingly, the information of both networks highlighted, aside from the metabolic potential of the strains, some of the challenges in the assignment of cyanobacterial BGCs, as despite the fact that the

majority of the molecular families had a spectral match, many BGCs were still orphans. Specifically, a variety of peptides were predicted in the BGC analysis, while in the metabolomics analysis, they were underrepresented compared to lipidic molecules. This pointed out the need for advanced genomic engineering approaches to enhance the production of the cryptic peptides or to develop strategies to facilitate their detection.

The power of genome and metabolome mining strategies can be complemented with further omics technologies. Peptidogenomics and *de novo* peptide sequencing are emerging as new approaches linking peptides with MS data through automated processes in tools like NRPquest⁷⁷ for NRPS or MetaMiner⁷⁸ and DeepRipp⁷⁹ for RiPPs. Although proteomics has been less integrated within the workflows, it can be useful to leverage the information of the enzymes involved in the biosynthesis of the secondary metabolites. Available metadata about the samples can inspire experiments and guide the



prioritisation. This can include taxonomy and phylogenetics, as we have seen, but also bioactivity, growth conditions, and phenotypes of mutant strains. As shown, the majority of studies on cyanobacteria follow the pattern-based approach, focusing on the presence/absence of metabolites and BGCs across strains. However, other methods can further explore cyanobacteria, such as the correlation-based approach, which adds metrics to score a given BGC-metabolite connection (metabologenomics),⁸⁰ and the feature-based approach, supported by *in silico* tools and metabolite prediction, as the multi-omics study previously described.⁷² The above mentioned peptidogenomics approach also falls into this category. Another emerging method is the combination of feature and correlation-based approaches like applied by the NPLinker software framework.⁸¹ Through many advances in omics technologies, bioinformatics and machine learning, the opportunities for mining the untapped biosynthetic potential of cyanobacteria natural products are steadily increasing.

6. Endogenous activation of cryptic biosynthetic gene clusters in native cyanobacterial hosts

As emphasized above, studies on the model strain *N. punctiforme* PCC 73102 have shown that a major reason for the lack of assignment of the cryptic specialized metabolites is the low expression level of the majority of BGCs under standard growth conditions.^{43,53} It is likely that this is also true for many other talented cyanobacterial strains. A simple way for genome-based discovery for previously cryptic metabolites is to compare different cultivation conditions (OSMAC – one strain-many compounds).⁸² This can involve, for example, changing the composition of macro-, micro- or trace elements in the medium, altering the physical parameters, or testing different chemical elicitors and environmental cues.⁸² In addition, there are numerous examples of stimulation of BGCs by biotic interactions.⁸² In this context, interactions with other bacteria as well as interactions with eukaryotic organisms can induce or alter the expression of specialized metabolites. In the field of cyanobacterial research, there are few systematic or comprehensive studies on the influence of growth conditions; rather, it is individual studies that show the potential of this methodological approach.

A group of metabolites in cyanobacteria that can be induced by changing the macro elemental composition in the growth medium are siderophores that are stimulated by iron deprivation. Until recently, very few cyanobacterial siderophores were known such as the hydroxamate siderophores schizokinen and synechobactin and the catecholate siderophore anachelin.⁸³ A recent study that has used a genome-based approach led to the discovery of cyanochelins, a family of NRPS-derived siderophores containing β -hydroxyaspartate moieties (Fig. 5, 9).⁸⁴ Further, changing the trace elemental composition can elicit production of specialized metabolites. An impressive example was recently shown for the eagle-killing toxin aetokthonotoxin (AETX).⁸⁵ While the toxin was detected in environmental

samples growing on the invasive water plant *Hydrilla verticillata*, it could not be identified in isolated laboratory strains. The addition of potassium bromide to the medium resulted in stimulation of AETX production.⁸⁵ However, the reasons for the stimulating influence are different for the siderophore example and the AETX example. While the former are transcriptionally stimulated by iron deficiency, since the corresponding BGCs are typically controlled by specific transcription factors of the Fur family,⁸³ bromide is a direct precursor of AETX, without which production of the toxin is not possible.⁸⁵

Changing physical parameters during growth can also induce cyanobacterial specialized metabolites. Well-known examples of such inducible metabolites are the sunscreen compounds scytonemin (Fig. 5, 10) and mycosporic acids (MAAs, Fig. 5, 11).⁸⁶ While MAAs are also known from other phyla such as fungi, microalgae, macroalgae and heterotrophic bacteria, scytonemin is exclusively synthesized by cyanobacteria.⁸⁶ Scytonemin responds rather specifically to induction by UV-A and B,⁸⁷ while MAAs are induced by various stress conditions including UV stress, salt stress and desiccation,⁸⁸ MAAs are widespread among cyanobacteria and have been described in numerous variants. The inducibility of sunscreen compounds has been investigated both using laboratory strains and in field studies and is generally linked to the induction of transcription.^{89,90} Production of scytonemin, in particular, seems to be highly relevant for the adaptation to the extreme light conditions in deserts and is able to filter out damaging UV light portions. Scytonemin production was also linked to localized warming in soil crust communities.⁹⁰ In addition to their ecological significance, scytonemin and MAAs are also among the cyanobacterial metabolites with potential for application in cosmetics and medicine.⁸⁶

A combination of chemical and physical parameters again is changed by the above-mentioned HD cultivation. In this cultivation apparatus, both high light irradiation and higher amounts of the carbon source CO₂ are being used. In addition, cyanobacteria grow as a dense biofilm. The use of this cultivation technology in *N. punctiforme* PCC 73102 and other *Nostoc* strains led not only to efficient growth but also reprogramming of specialized metabolism, both qualitatively and quantitatively.^{43,53} Transcriptional analysis of BGCs revealed that at least 50% of BGCs were strongly stimulated under these conditions and that a combination of high light conditions, high CO₂ availability and medium factors are triggering both transcription and production of compounds.⁵³ As proof of principle, HD cultivation of the strain *Nostoc* sp. KVJ2 led to the discovery and structural elucidation of three new anabaenopeptin variants, KVJ827 (Fig. 5, 12), KVJ841 and KVJ811 which showed allelopathic activity against other *Nostoc* strains from the same habitat.⁴³

The influence of biotic interactions on the production of specialized compounds in cyanobacteria is generally poorly studied. The fact that many talented producers still have accompanying heterotrophic bacteria and that the effects of specific interactions are thus difficult to dissect certainly plays a role here. A comparison of axenic toxic and nontoxic *Microcystis* strains in mono- and coculture revealed an intraspecific






Fig. 5 Examples of cultivation-based discovery of cyanobacterial metabolites following BGC activation by iron limiting cultivation conditions, UV induction or high-density cultivation.

quantitative variation of major peptide classes and led to the discovery of new cyanopeptolin analogues.⁹¹ Co-cultivation of *Microcystis* with a heterotrophic bacterial community again resulted in negligible effects on the intracellular specialized metabolome. Remarkably, no extracellular levels of the known peptide classes in *Microcystis* were detected when the cyanobacterium was accompanied by a heterotrophic consortium suggesting an ability of the community to degrade structurally different compounds or a physiological suppression of their secretion.⁹² Hence, while intra- and interspecific biotic interactions certainly have an impact on the intra- and extracellular metabolome of *Microcystis*, they did not lead to the genome-based discovery of entirely new classes of compounds. A comparison of the metabolome of the symbiotic cyanobacterium *N. punctiforme* in the free-living state and in physical association with the plant host *Gunnera manicata* using MALDI-

imaging showed major differences in the metabolite profiles with nostopeptolides being downregulated and a number of novel metabolites being upregulated *in planta*.⁹³ Since only limited amounts of symbiotic tissue were available the study did not lead to the description of a new metabolite family either. Yet, it gives hints that biotic interactions with eukaryotic partners may lead to a more pronounced impact on the specialized metabolome than interaction with other prokaryotes.

In summary, cultivation-induced biodiscovery is a promising approach for cyanobacteria. However, there are only incidental studies with a focus on single factors. To generalize conclusions regarding the impact of abiotic and biotic factors on the specialized metabolome high throughput approaches are needed using a highly parallelized approach. Development of such approaches requires minimization of culture volumes and ideally includes an automated control of cultivation



conditions.⁸² One methodology that is now commonly used for other microorganisms is the microfluidics technology.⁸² Although this technology requires optimization for filamentous cyanobacteria, it could provide a means for semi-automated analysis of cyanobacteria in a miniaturized format. Thereby, both the impact of abiotic factors as well as biotic factors could be tested in a larger format. There are certainly additional ways to rationalize metabolite induction. The AntiSMASH platform already gives some hints on the possible specificity of transcription factors and their regulation.²² There is also much evidence that environmental cues commonly present in the habitat of the given organisms may play a particular role in the induction of specialized metabolites. Ultimately, it depends on the range of biological and metabolic properties of individual strains, which conditions could lead to an altered special metabolite profile. Since variations in cultivation conditions are easily feasible for cyanobacteria of all genera and habitats, the general potential of cultivation-based approaches is far from exhausted.

7. Use of genetic approaches for the discovery and manipulation of cyanobacterial natural products

Genetic techniques have contributed to significant progress in microbial natural product research, ultimately advancing natural product discovery and enabling the development of production strains, *e.g.* for Streptomyces and filamentous fungi.^{90,94,95} In principle, BGCs and their products can be assigned by forward genetic approaches with untargeted random mutagenesis or by reverse genetic approaches with targeted gene manipulation. Genetic techniques can also enable the activation of silent BGCs or be used to generate transcriptional reporters.⁹⁶ Since only a few cyanobacterial strains have been amenable to genetic manipulation to date, the scope of related studies in cyanobacteria is comparatively limited. However, endogenous activation of BGCs offers several advantages over heterologous expression. When BGCs are being activated in the native host, it can be assumed that precursors should be available even for biosynthetic pathways that are difficult to predict or that require enzymes encoded *in trans* of the BGC. Activation or inactivation of BGCs in the native cyanobacteria also allows the study of the biological function of their products. In addition, studies on the regulation of BGCs may also inspire future development of cyanobacterial production strains.

One of the few strains with great potential for natural products production that is accessible to genetic manipulation is the symbiotic strain *N. punctiforme* PCC 73102. For this strain, a library of transcriptional reporter mutants could be generated, in each case fusing the 5'UTR region containing the putative promoter region of BGCs of the NRPS, PKS, or RiPP types with the CFP reporting gene.⁵³ As mentioned above, this reporter library was used to test the transcriptional response to HD cultivation in high throughput format. Because several RiPP reporting strains showed a pronounced upregulation after HD

cultivation, the study was combined with a targeted metabolomic search for the hypothetical RiPP products. Thereby, the new microviridin N1–N9 variants were discovered (Fig. 6, 13).⁵³ Microviridins had previously been described primarily in *Microcystis* and *Planktothrix*, but microviridins of *N. punctiforme* are distinguished by a variable chain length at the N-terminus and were overlooked prior to the reporter-guided study. While this is an example how transcriptional reporters can facilitate genomic mining of novel compounds there are certainly further ways to use the library in the future, such as BGC elicitor screening or screening of biotic interactions with either prokaryotic or eukaryotic organisms.

Strain *N. punctiforme* PCC 73102 (alternatively designated as *N. punctiforme* ATCC 29133) was also the only strain in which a cyanobacterial natural product BGC could be assigned using a forward genetic approach. The biosynthetic pathway for the sunscreen compound scytonemin was originally discovered using random transposon mutagenesis.⁸⁷ Besides, several BGCs could be inactivated in non-model cyanobacteria using a directed reverse genetic approach. First, the microcystin biosynthetic pathway was knocked-out in the genus *Microcystis*.⁹⁷ In the same genus, the BGCs for aeruginosin,⁹⁸ micropeptin,⁹⁹ and MAA⁸⁸ were also successfully manipulated. Notably, mutagenesis has only been successful in two *Microcystis* strains: *M. aeruginosa* PCC 7806 and *M. viridis* S-70.⁹⁹ Other cyanobacterial BGCs that could be inactivated include the anabaenopeptilide BGC in *Anabaena* sp.^{91,100} the microcystin and aeruginoside BGCs in *Planktothrix* NIVA-Cya126 (ref. 101 and 102) and the *pks2* BGC in *N. punctiforme* PCC 73102.¹⁰³ In all cases, mutagenesis contributed to the assignment of natural products and their BGCs. Only in the case of the cryptic *pks2* BGC of *N. punctiforme* PCC 73102, no product could be assigned so far, probably due to the low expression level of the BGC.⁵³ In some cases, mutagenesis has contributed essential insights into the biosynthetic mechanism. For example, mutagenesis of the *aerD*, *E*, and *F* genes and subsequent feeding experiments demonstrated their involvement in the biosynthesis of the characteristic Choi moiety of aeruginosins in *P. agardhii* NIVA-Cya 126 (Fig. 6, 14).¹⁰² Mutagenesis of the tailoring enzyme McyJ in *P. agardhii* NIVA-Cya126 allowed isolation of microcystins lacking the *O*-methylation at the ADDA moiety (Fig. 6, 15), thereby identifying McyJ as responsible *O*-methyltransferase.¹⁰¹

As mentioned earlier, a positive side aspect of biosynthetic mutants is their potential for studies of biological function. In particular, the microcystin-free Δ *mcyB* mutant has been intensively used for years for research on microcystin function. In this context, a close connection of microcystin with primary carbon exchange could be demonstrated. In cyanobacteria, the toxin binds to key proteins of the Calvin–Benson–Bassham cycle including the CO₂-fixing enzyme RubisCO.¹⁰⁴ MAA mutants were also used for functional analyses. It was shown that the loss of MAA did not affect growth under UV stress, but did affect the structure of the EPS layer of strain *M. aeruginosa* PCC 7806. This observation strengthens the hypothesis that MAA is not produced primarily for UV protection and that the sunscreen effect may be a useful side effect of the compound family.⁸⁸ The






Fig. 6 Examples of cyanobacterial metabolites discovered or studied in cyanobacteria using genetic tools in the original producers. Moieties whose biosynthesis was characterized by gene knock-out are highlighted in red.

pks2-mutant was used as an indirect tool to explore the role of nostopeptolide in *N. punctiforme* PCC 73102. Since nostopeptolide was greatly reduced in the mutant, it was shown that nostopeptolide represses or stimulates the development of motile hormogonia filaments in a concentration-dependent manner, thereby having a significant impact on the symbiotic interaction of *N. punctiforme* with the host *Gunnera manicata*.⁹³ Loss of constitutively produced cyanopeptides often leads to increased production of other cyanopeptides, apparently because unused resources become available. For example, loss of microcystin in *M. aeruginosa* PCC 7806 leads to increased production of cyanopeptolin and microcyclamides,⁹¹ and loss of anabaenopeptolide in strain *Anabaena* 90 leads to increased production of anabaenopeptin.¹⁰⁵ These observations may also contribute to the optimization of production strains in the future.

The strain *N. punctiforme* PCC 73102 is also suitable for overexpression of transcriptional regulators. There are shuttle plasmids that replicate in both *E. coli* and *N. punctiforme*. Applying a shuttle plasmid technology, it has recently been possible to overexpress an AraC type positive regulator for the

previously cryptic *pks1* pathway.¹⁰⁶ Upregulation of the *pks1* pathway, in turn, led to the global stimulation of the specialized metabolism in *N. punctiforme*, in particular under high density cultivation conditions. To identify the responsible signals, a reporter mutant was used to evaluate the response of the *pks1*-dependent cryptic lanthipeptide pathway ripp4. The bioactivity-targeted strategy led to the discovery and high titer production of two signal molecules: nostovalerolactone (Fig. 6, 16), representing a new family of compounds derived from a tetronate-like pathway in *N. punctiforme*, and nostoclides N1 and N2, representing new members of the cyanobacterin family (Fig. 6, 17).¹⁰⁶

Although only a few strains are amenable to genetic manipulation, insights gained through genetic analyses can be very helpful in making screening of cyanobacterial extracts more efficient and in developing individual strains for synthetic biology applications. However, further research and development is needed to catch up to known microbial model systems such as in *Streptomyces* or *Aspergillus* strains.^{94,95} For the further development of individual strains as production strains, knowledge on the regulation of secondary metabolism must be



further deepened. The power of engineering strategies that exploit underlying regulatory mechanisms for the targeted overproduction of individual substances has been demonstrated, for example, for proteobacteria of the genera *Xenorhabdus* and *Pseudomonas*. Once it was known that BGC expression was primarily controlled post-transcriptionally, knocking out the RNA chaperone Hfq was able to abolish global production of specialized compounds. Against this background, individual BGCs can be specifically activated and optimized.¹⁰⁷ Similar strategies are also conceivable for individual cyanobacterial strains in the future and can greatly advance the biotechnological potential of cyanobacteria for the production of bioactive natural products.

8. Heterologous expression: *E. coli* vs. cyanobacterial hosts

Despite advances in the development of genetic tools for cyanobacteria, their application is limited to very few strains. Furthermore, most of the bioactive natural products can only be isolated at low yields thus hampering economical large-scale production and development of routines that ultimately could lead to commercial applications. The aforementioned problem of the enormous untapped potential hidden away in “orphan” or “silent” BGCs further exacerbates the need for alternative methods to make cyanobacteria live up to their expectations. In this regard, heterologous expression of cyanobacterial BGCs is an increasingly successful avenue (most recently reviewed in ref. 55), albeit the number of relevant studies is small and lags significantly behind the *in silico* identification of novel BGCs. In particular, the list of heterologous host organisms is short and can roughly be divided in cyanobacterial and non-cyanobacterial hosts. While the latter group is dominated by the biotechnological mainstay *E. coli*, the former includes the cyanobacterial “models” *Synechocystis* sp. PCC 6803, *Synechococcus elongatus* PCC 7942 and *Anabaena* PCC 7120. Organisms from other clades have also been used, most notably yeast¹⁰⁸ and *Streptomyces venezuelae* DHS 2001,¹⁰⁹ but these are clearly the exception. Choosing the host best suitable for the expression of a given BGC is critical, however, owing to the complex requirements of individual biosynthetic pathways, there is currently no reliable method to predict the outcome before experimental validation. Therefore, it is important to gather all available information about the target BGC and its product range to infer specific requirements regarding, among others, substrate availability, medium composition or genetic compatibility.

Unsurprisingly, early attempts at heterologous expression of cyanobacterial natural products have focused on RiPPs as their BGCs are comparably small and as such easily handled by established molecular biological techniques. Moreover, RiPPs solely rely on the presence of proteinogenic amino acids and the ribosomal translational machinery,¹¹⁰ their BGCs normally encode all enzymes necessary for post-translational product modification and they do not require activation by off-site factors. Consequently, RiPPs make up a large proportion of cyanobacterial natural products that were reported to be

produced heterologously.^{111–118} In these pioneering works, *E. coli* was the obvious choice of expression host as the BGCs were introduced on established vectors with little or no modifications necessary to the genetic sequences or the host metabolism. This situation is drastically different when BGCs of the NRPS and/or PKS type are to be analyzed. Not only do these gene clusters tend to be much larger than those of RiPPs, which makes cloning more difficult,¹¹⁰ but there is also a certain degree of incompatibility between elements of transcriptional regulation, most prominently promoters, from cyanobacteria and *E. coli*.^{110,119–121} The most important impediment, however, is that the metabolism of *E. coli* needs to be primed for the expression of NRPS/PKS type of BGCs, primarily because they require the activity of a suitable phosphopantetheinyl transferase (PPTase) to activate their cognate carrier proteins.^{122,123} In connection to that, the introduction of additional factors is often needed to meet the substrate and co-factor requirements of each individual BGC as they tend to rely on the availability of rare non-proteinogenic amino acids or their precursors. In a case-dependent manner, these problems can be solved either by supplying the necessary factors with the growth medium or by genetically engineering the host metabolism to provide off-site auxiliary enzymes. Despite this, *E. coli* has undeniable advantages that still uphold its attractiveness as a host for BGC heterologous expression. The most convincing arguments for *E. coli* are the plethora of well-established genetic tools, the straightforward cultivation and the short doubling times. Accordingly, many attempts have been made to adapt *E. coli* to the expression of large BGCs and to rationalize workflows. Recent advances in DNA assembly, for instance, have facilitated the handling of large genetic constructs. A method based on Gibson assembly termed “direct pathway cloning” (DiPaC,^{124–126} and the transformation-associated recombination (TAR) approach)^{127,128} have successfully been employed to capture large BGCs. The necessity to provide a constitutive PPTase has also been addressed by the generation of two widely used *E. coli* strains, BAP1 (ref. 129) and GB05-MtaA,¹²⁰ which express promiscuous Sfp-type PPTases from *Bacillus subtilis* and the myxobacterium *Stigmatella aurantiaca*, respectively. With these tools in hand, a number of NRPS/PKS derived cyanobacterial compounds have been successfully produced in *E. coli*. Among those are the dermatotoxin lyngbyatoxin (Fig. 7, **18** (ref. 130)), the infamous hepatotoxin microcystin-LR (**1**),^{120,131} the depsipeptide hapalysin (Fig. 7, **19** (ref. 132)) and, most recently, the natural herbicide cyanobacterin¹²⁴ and the protease inhibitor microginin.¹²⁵ Frequently, the products detected in *E. coli* did not fully reflect the compound spectrum found in the natural producers, however, these expression systems still can provide very valuable mechanistic insight (*e.g.* with cyanobacterin¹²⁴) or can serve in establishing an accessible platform for combinatorial production of novel congeners (*e.g.* with microcystin-LR¹³¹). Therefore, *E. coli* will doubtlessly continue to maintain its status of a major heterologous expression system, as evidenced by the high number of current research efforts in that field.

Despite the accessibility and adaptability of the *E. coli* system, there have been many examples where the production



of cyanobacterial natural product proved to be very troublesome or downright impossible. The resulting demand of alternative expression systems is best illustrated with the case of lyngbyatoxin A, an NRPS-type compound and promising drug lead.¹³³ While its heterologous production was altogether unsuccessful in *Streptomyces coelicolor*¹³⁴ and required the exchange of the cyanobacterial native promoters in *E. coli*,¹³⁰ it was easily achieved in the filamentous cyanobacterium *Anabaena* sp. strain PCC7120 (*Anabaena* 7120,¹²⁸). This follows the widely accepted notion that heterologous expression of complex metabolites is best carried out in hosts more closely related to the original producer. As a number of cyanobacterial model strains with fairly advanced genetic tools have been available for more than two decades, scientists have started to investigate these strains for their suitability as expression hosts for natural product BGCs. The three most widely used strains of cyanobacteria are *Synechocystis* sp. PCC 6803 (*Synechocystis*), *Synechococcus elongatus* PCC 7942 (*S. elongatus*) and *Anabaena* 7120 and indeed, heterologous expression of cyanobacterial BGCs has been attempted in all of them (Fig. 7). Gauging the success of these approaches, however, *Anabaena* 7120 has emerged as the clear

favorite. While there are two reported cases where *Synechocystis* and *S. elongatus* were employed for the successful production of small or partial BGCs such as the MAA shinorine (Fig. 7, 20 (ref. 135)) and a sponge-derived polybrominated diphenyl ether (Fig. 7, 21 (ref. 136)), in recent years the products of complex, full-size NRPS/PKS-type BGCs were isolated with comparably high yields from *Anabaena* 7120. In retrospect, this does not seem very surprising, because the genus *Anabaena* displays a number of traits that appear to be beneficial for the production of NRPS/PKS type compounds and that are absent from the two other strains. First and foremost, while *Anabaena* encodes several NRPS/PKS BGCs¹⁵ together with an active, very promiscuous Sfp-type PPTase,¹²³ it does not seem to produce any bioactive compounds that may potentially disturb expression of foreign BGCs.¹²⁸ Additionally, many cyanobacterial promoters seem to work well in *Anabaena* 7120 and its genetic toolbox is constantly being expanded.^{128,137–140} With their groundbreaking work, two groups in particular have paved the way in establishing *Anabaena* 7120 as a promising host for the heterologous expression of cyanobacterial natural products. Implementing their lyngbyatoxin expression platform, Philmus and coworkers




Fig. 7 Examples of cyanobacterial metabolites heterologously produced in either *E. coli* strains or cyanobacterial model strains.



were not only the first to report the successful heterologous production of a complex NRPS-type compound in *Anabaena* 7120, they were also able to take their system a step further, employing biocombinatorics to produce additional indolactam-V derivatives by swapping in tailoring enzymes from different genera.^{127,128} Most recently, the group reported the successful production of the meroterpenoid tolypodiol and some of its analogs from a 21 kb BGC.¹⁴¹ While in these cases the BGCs were expressed from replicative plasmids, Golden and colleagues have successfully produced cyanobacterial compounds from BGCs that were integrated into a neutral site of the chromosome of *Anabaena* 7120. In their first reported case, they initially attempted to have *S. elongatus* produce the putative anti-infective compound cryptomaldamide (Fig. 7, 22) from a 28.7 kb NRPS/PKS megasynthase BGC.¹⁴² Despite many efforts to induce biosynthesis, they were only successful once they changed the heterologous host to *Anabaena* 7120. More recently, the group utilized their expression system for the production of columbamides (Fig. 7, 23), a family of chlorinated acyl amides, from a 28.5 kb NRPS/PKS hybrid BGC.¹⁴³ What makes this study stand out is the fact that apart from the discovery of new high potential compound analogs, the BGC in question was merely proposed, at the time, to code for the columbamide pathway and was thus experimentally confirmed by heterologous expression.

Evidently, substantial progress has been made in recent years, with both the *E. coli* and the cyanobacterial system. Both offer certain advantages over the other, with *E. coli* being better established and more accessible and cyanobacteria holding more promise with regard to enzyme fidelity and product biochemistry. Both systems suffer from a lack of predictability, as there are still no clear indicators available from which to infer host compatibility or to estimate production levels. Indeed, so far neither system has proven to be advantageous in this respect, as examples for very high and very low yields have been reported for both.⁵⁵ The most convincing argument in favor of cyanobacteria as heterologous host, not only for natural product research, is the great potential for sustainable, green biotechnology. From the progress that has been made in recent years and with cyanobacterial expression systems being now in the focus of many efforts to optimize their handling and performance, the development of potentially carbon-negative production strains that can offset the advantages that *E. coli* still holds, seems to be only a matter of time. This could also go a long way towards fully unlocking the cyanobacterial natural product potential by finally enabling the systematic introduction of orphan BGCs into heterologous hosts and the identification of their cognate natural products.

9. From *in vitro* reconstitution of cyanobacterial pathways to chemo-enzymatic exploitation

In view of the challenges discussed above for the mining and study of cyanobacterial natural products, the *in vitro* reconstitution of key biosynthetic steps or even entire biosynthetic

pathways, sometimes referred to as “total biosynthesis”,¹⁴⁴ offers an elegant solution for the characterization of BGCs or the production of bioactive compounds when biochemical reactions and precursors for the assembly of compounds are known or well predictable. Similar to the approaches discussed earlier, this emerging field is benefiting greatly from continued advances in biotechnology, computation, and analytics. In addition, innovation is fueled by the chemical and pharmaceutical industries' growing appetite for biocatalysts as drivers of green and sustainable chemistry.¹⁴⁵

Recent elegant examples of *in vitro* reconstitution of cyanobacterial pathways are the aforementioned eagle-killing toxin aetokthonotoxin (Fig. 8, 24),¹⁴⁶ the core of the bioherbicide cyanobacterin (Fig. 8, 25),¹²⁴ or the potent anticholinesterase neurotoxin guanitoxin (Fig. 8, 26).¹⁴⁷ For the biosynthesis of aetokthonotoxin (AETX) Adak and Lukowski *et al.* showed that the freshwater cyanobacterium *Aetokthonos hydrillicola* uses an efficient, five-enzyme biosynthetic pathway to convert two molecules of tryptophan to yield this structurally unique pentabrominated biindole nitrile by assembling two functionalized indole monomers that are then linked by biaryl coupling.¹⁴⁶ Of the five biosynthetic enzymes, two stand out for their potential as biocatalysts, namely the unique single-component, flavin-dependent tryptophan halogenase AetF, which does not require an accompanying reductase partner, and the iron-dependent nitrile synthase AetD, which builds a nitrile functional group *via* unprecedented rearrangement chemistry. In addition to revealing novel chemistry, the identification of the AETX BGC may help to identify related BGCs and thus help to discover new environmental toxins.

When the potent photosynthesis inhibitor cyanobacterin was isolated from *Scytonema hofmanni* in 1982 it was the first chlorinated natural product identified from freshwater cyanobacteria.¹⁴⁸ Four decades later D'Agostino *et al.* took advantage of this property and identified the cyanobacterin (*cyb*) biosynthetic gene cluster by targeted bioinformatic screening for halogenase-encoding genes.¹²⁴ After validation of the BGC by heterologous expression in *E. coli*, the authors were able to break down the biosynthesis of the furanolide core structure to four enzymes by gene knockouts and the development of a one-pot biocatalytic *in vitro* synthesis. At the heart of the reaction sequence the furanolide synthase CybF fuses two molecular building blocks, which are provided by CybB, CybC and CybE to form the furanolide core. Since members of the furanolide natural product family such as nostoclidides^{106,149} or maculalactones¹⁵⁰ are more widespread in cyanobacteria, the elucidation of furanolide biosynthesis paves the way for their targeted discovery, biosynthetic engineering and enzymatic synthesis.

Guanitoxin and cyanobacterin have in common, that their BGCs have remained elusive for decades. To identify candidate guanitoxin BGCs in *Sphaerospermopsis torquesreginae* ITP-024, Lima *et al.* focused on genes associated with the known guanitoxin precursors (*S*)-4-hydroxy-L-arginine and L-enduracididine.¹⁴⁷ This led to the identification of a candidate *gnt* BGC whose involvement in guanitoxin biosynthesis was confirmed by the impressive *in vitro* reconstitution of a nine-






Fig. 8 Examples of cyanobacterial metabolites whose biosynthesis could be elucidated by enzymatic or chemo-enzymatic reconstitution. The enzymes can be used for diversification and functionalization of the respective metabolite classes. Cyanobacteria encode unprecedented enzymes, such as PlpXY splicase, whose reaction is highlighted in red.

step metabolic pathway starting from *L*-arginine. The elucidation of the genetic basis of guanitoxin biosynthesis now allows environmental biosynthetic gene monitoring of this lethal neurotoxin, which shares an identical mechanism of action with the synthetic chemical warfare agent sarin and is one of the most potent cyanotoxins known today.

These three studies are prime examples of how *in vitro* reconstitution can help to elucidate biosynthetic pathways. However, the *in vitro* reconstitution of individual enzymatic steps or biosynthetic sequences also offers the possibility of exploiting these pathways chemo-enzymatically. Among the diverse compound classes found in cyanobacteria, RiPPs are particularly well suited for this approach due to the synthetic accessibility of precursor and core peptides by solid-phase peptide synthesis (SPPS), the hypervariability of the peptides, and the relaxed substrate specificity and modularity reported for many RiPP-modifying enzymes.

A recent study perfectly exemplifies the great potential of combining hypervariable precursor peptides with highly

promiscuous RiPP-modifying enzymes *in vitro*. By incubating 120 peptide substrates from a synthetic positional scanning library with the macrocyclase PagG and the prenyltransferase PagF from the cyanobactin prenylagaramide biosynthetic pathway Sarkar *et al.* generated a library of more than 100 prenylagaramide-like cyclic peptides and their prenylated derivatives.¹⁵¹ Interestingly, the promiscuity of cyanobactin prenyltransferases towards the prenyl donor can also be exploited chemo-enzymatically. For this, a synthetic alkyl pyrophosphate analogue was used to introduce a reactive moiety into a tryptophan-containing cyclic peptide. This reaction was catalysed by the N1-tryptophan prenyltransferase AcyF from the anacyclamide A8P pathway. After the conversion, click chemistry was used to fluorescently label the enzymatically modified peptide.¹⁵²

Another cyanobacterial RiPP family that has been the subject of multiple chemo-enzymatic studies are the graspetides. These compounds, which include microviridins, are defined by the presence of ester or amide side-chain linkages that are installed



by ATP-grasp ligases, resulting in peptide macrocycles.¹⁵³ While the ATP-grasp ligases in microviridin biosynthesis catalyse cyclisation reactions in strict order and with stringent ring size requirements, they tolerate variations in the amino acid composition of the core peptide.¹⁵⁴ This property was exploited by Reyna-González *et al.* in the synthesis of a microviridin-based library of protease inhibitors.¹⁵⁵ In one-pot chemo-enzymatic reactions synthetic microviridin K and microviridin B core peptides, varied by all 20 proteinogenic amino acids at the position responsible for protease specificity, were transformed by two ATP-grasp ligases that were constitutively activated by covalently attached leader peptides, and a GNAT-type *N*-acetyltransferase. This leader peptide-free approach, which was inspired by a study from lantibiotic biosynthesis¹⁵⁴ is highly efficient, since the relatively short core peptides can be synthesized much easier and at reduced costs compared to full-length RiPP precursor peptides. Later, the chemo-enzymatic synthesis platform was used to synthesize four microviridins encoded by the cyanobacterium *Cyanothece* sp. PCC 7822, providing a powerful example of culture-independent genome mining.¹⁵⁶ In addition, Scholz *et al.* used the platform to introduce functional tags into different microviridin variants with the help of modified core peptides, yielding biotinylated, dansylated or propargylated congeners as tool compounds to further investigate the biology of microviridins.¹⁵⁷ As a proof of concept, dansylated microviridin B (Fig. 8, 27) was used as a diagnostic tool to selectively label elastase in protease mixtures.

The examples given in this section illustrate how *in vitro* enzyme reconstitution facilitates the study and exploitation of cyanobacterial metabolic pathways. However, cyanobacteria also exhibit amazing enzymology that could be exploited beyond single pathways. A remarkable example is the discovery of non-canonical protein splicing by the radical *S*-adenosylmethionine (rSAM) enzyme PlpX from *Pleurocapsa* sp. PCC 7319. In a recent study Morinaka *et al.* showed that PlpX, together with the helper protein PlpY, catalyzes backbone carbon-carbon bond cleavage and the net excision of tyramine, resulting in the formation of α -keto- β -amino acids (Fig. 8).¹⁵⁸ The reaction has been used to incorporate diverse and multiple β -amino acids into various RiPP precursors and recombinant proteins in *E. coli*.^{158,159} In addition to expanding the set of basic amino acid building blocks in peptidic natural products and proteins, tyramine splicing yields keto functions that can be readily exploited as orthogonal reaction sites for chemical diversification.^{158,160}

Another impressive example of unprecedented enzyme catalysis in the biosynthesis of secondary metabolites comes from *Cylindrospermum licheniforme* ATCC 29412. Nakamura *et al.* were able to show that in cylindrocyclophane biosynthesis, chlorination of an unactivated carbon center by the halogenase CylC sets the stage for an enzymatic dimerization reaction catalyzed by CylK.¹⁶¹ This reaction features sequential, stereospecific alkylations of resorcinol aromatic rings by the alkyl halide electrophiles.^{161,162} Notably, alkylation of aromatic rings with alkyl halides is an important transformation in organic synthesis. However, an enzymatic equivalent was unknown.

Interestingly, homologs of CylC and CylK cluster together with a number of additional enzymes in other unrelated cyanobacterial gene clusters, suggesting that related C-C bond formation strategies involving cryptic chlorination may be more widespread in the biosynthesis of cyanobacterial secondary metabolites.¹⁶¹ This, together with the prominent role of aryl-alkyl bonds in pharmaceuticals and industrial chemicals, makes CylC and CylK promising targets for future efforts in biocatalysis and metabolic engineering.

The selected enzymatic studies underline the extraordinary biosynthetic potential of cyanobacteria. As emphasized already, *in vitro* reconstitution is independent of cultivation and therefore applicable to the broad mass of cyanobacterial natural product producers. If the transformation of substrates succeeds *in vitro*, a wide range of possibilities for diversification and functionalization of metabolites arise. However, the amounts of substrates and their conversion cannot be arbitrarily upscaled. Individual chemical reactions, for example in the chemical synthesis of peptide precursors by solid-phase peptide synthesis, are also not very environmentally friendly. Therefore, *in vitro* (bio)synthesis is not always the appropriate method of choice. However, its importance for the study of biosynthetic mechanisms is central. In particular, linkage with structural biology analyses of enzymes can rationalize the production of new-to-nature libraries of metabolites. Enzymes are at the core of cyanobacterial natural product research and provide a hub for further exploitation.

10. Conclusions

In the last two decades, cyanobacterial natural products research has evolved on many levels. The majority of known natural product families could now be assigned to their dedicated GCFs. Public access to this information has enabled expansion and refinement of methods for dereplication of cyanobacterial datasets and provides avenues for prioritization of metabolite families. At the same time, technologies for cyanobacterial cultivation and genetic manipulation have advanced. Above all, heterologous expression of BGCs has made much progress in recent years. However, there are major areas of cyanobacterial natural products research that lag significantly behind comparable research in other microbial phyla. In particular, few entirely new classes of natural products have been discovered and described by genome-based approaches. Also, the development of production strains for natural products from cyanobacteria is still in its infancy. This is particularly striking because synthetic biology and biotechnology of cyanobacteria is a successful research and business field, and cyanobacteria are expected to contribute significantly to the development of a circular bioeconomy.

This discrepancy is due to the strong focus in engineering tool development on a few unicellular cyanobacterial model strains. Future cyanobacterial natural products research needs to drive method development for appropriate filamentous strains themselves. This path is already being followed for the strain *Nostoc* sp. PCC 7120 and *N. punctiforme* PCC 73102. So far, these attempts are hardly on par with heterologous expression



of cyanobacterial BGCs in *E. coli*. However, studies on production strains in e.g. Actinobacteria and Proteobacteria have shown that there is still much room for improvement in the optimization of production titers in original producers. This effort is definitely worthwhile because it can give new impulses to the whole cyanobacterial natural product research and biotechnology. To this end, the spectrum of suitable strains should be expanded and insights into the regulation of BGCs should be further gained and explored. These efforts also depend on understanding microbial physiology and biotic interactions among strains. In this way, microbiology potentially plays a key role in future cyanobacterial natural products research.

11. Author contributions

E. D. conceived the review, E. D., M. B., A. G. and M. M. G. wrote the review and contributed illustrations.

12. Conflicts of interest

There are no conflicts to declare.

13. Acknowledgements

This study was supported by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – Project-ID 239748522 – SFB 1127 to E. D. and by the DFG-funded graduate school RTG 2473 (Bioactive Peptides) to E. D. M. B. is supported by Germany's joint federal and state program supporting early-career researchers (WISNA).

14. References

- 1 P. Sanchez-Baracaldo, G. Bianchini, J. D. Wilson and A. H. Knoll, *Trends Microbiol.*, 2022, **30**, 143–157.
- 2 E. Dittmann, D. P. Fewer and B. A. Neilan, *FEMS Microbiol. Rev.*, 2013, **37**, 23–43.
- 3 K. Harada, M. Suzuki, A. M. Dahlem, V. R. Beasley, W. W. Carmichael and K. L. Rinehart Jr, *Toxicon*, 1988, **26**, 433–439.
- 4 J. Huisman, G. A. Codd, H. W. Paerl, B. W. Ibelings, J. M. H. Verspagen and P. M. Visser, *Nat. Rev. Microbiol.*, 2018, **16**, 471–483.
- 5 P. Rzymiski and B. Poniedzialek, *Postepy Dermatol. Alergol.*, 2012, **29**, 47–50.
- 6 R. E. Moore, *J. Ind. Microbiol.*, 1996, **16**, 134–143.
- 7 P. Hrouzek, P. Tomek, A. Lukesova, J. Urban, L. Voloshko, B. Pushparaj, S. Ventura, J. Lukavsky, D. Stys and J. Kopecky, *Environ. Toxicol.*, 2011, **26**, 345–358.
- 8 A. Liaimer, J. B. Jensen and E. Dittmann, *Front. Microbiol.*, 2016, **7**, 1693.
- 9 J. C. Kehr, D. Gatte Picchi and E. Dittmann, *Beilstein J. Org. Chem.*, 2011, **7**, 1622–1635.
- 10 K. Kleigrewe, L. Gerwick, D. H. Sherman and W. H. Gerwick, *Nat. Prod. Rep.*, 2016, **33**, 348–364.
- 11 P. M. D'Agostino, *Nat. Prod. Rep.*, 2023, **40**, 1701–1717.
- 12 J. Demay, C. Bernard, A. Reinhardt and B. Marie, *Mar. Drugs*, 2019, **17**, 320.
- 13 M. Schwark, J. A. Martinez Yerena, K. Rohrborn, P. Hrouzek, P. Divoka, L. Stenclova, K. Delawska, H. Enke, C. Vorreiter, F. Wiley, W. Sippl, R. Sobotka, S. Saha, S. B. Wilde, J. Mares and T. H. J. Niedermeyer, *Proc. Natl. Acad. Sci. U. S. A.*, 2023, **120**, e2219230120.
- 14 R. M. Hohlman and D. H. Sherman, *Nat. Prod. Rep.*, 2021, **38**, 1567–1588.
- 15 P. M. Shih, D. Wu, A. Latifi, S. D. Axen, D. P. Fewer, E. Talla, A. Calteau, F. Cai, N. Tandeau de Marsac, R. Rippka, M. Herdman, K. Sivonen, T. Coursin, T. Laurent, L. Goodwin, M. Nolan, K. W. Davenport, C. S. Han, E. M. Rubin, J. A. Eisen, T. Woyke, M. Gugger and C. A. Kerfeld, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 1053–1058.
- 16 A. Calteau, D. P. Fewer, A. Latifi, T. Coursin, T. Laurent, J. Jokela, C. A. Kerfeld, K. Sivonen, J. Piel and M. Gugger, *BMC Genomics*, 2014, **15**, 977.
- 17 E. Dittmann, M. Gugger, K. Sivonen and D. P. Fewer, *Trends Microbiol.*, 2015, **23**, 642–652.
- 18 A. Hitchcock, C. N. Hunter and D. P. Canniffe, *Microb. Biotechnol.*, 2020, **13**, 363–367.
- 19 C. J. Knoot, J. Ungerer, P. P. Wangikar and H. B. Pakrasi, *J. Biol. Chem.*, 2018, **293**, 5044–5052.
- 20 T. T. Selao, *J. Exp. Bot.*, 2022, **73**, 3057–3071.
- 21 M. Y. Chen, W. K. Teng, L. Zhao, C. X. Hu, Y. K. Zhou, B. P. Han, L. R. Song and W. S. Shu, *ISME J.*, 2021, **15**, 211–227.
- 22 K. Blin, S. Shaw, H. E. Augustijn, Z. L. Reitz, F. Biermann, M. Alanjary, A. Fetter, B. R. Terlouw, W. W. Metcalf, E. J. N. Helfrich, G. P. van Wezel, M. H. Medema and T. Weber, *Nucleic Acids Res.*, 2023, **51**, W46–W50.
- 23 A. Gavriilidou, S. A. Kautsar, N. Zaburanyi, D. Krug, R. Muller, M. H. Medema and N. Ziemert, *Nat. Microbiol.*, 2022, **7**, 726–735.
- 24 S. A. Kautsar, J. J. J. van der Hooft, D. de Ridder and M. H. Medema, *Gigascience*, 2021, **10**, g1aa154.
- 25 J. A. van Santen, E. F. Poynton, D. Iskakova, E. McMann, T. A. Alsup, T. N. Clark, C. H. Fergusson, D. P. Fewer, A. H. Hughes, C. A. McCadden, J. Parra, S. Soldatou, J. D. Rudolf, E. M. Janssen, K. R. Duncan and R. G. Linington, *Nucleic Acids Res.*, 2022, **50**, D1317–D1323.
- 26 D. H. Parks, M. Chuvochina, D. W. Waite, C. Rinke, A. Skarshewski, P. A. Chaumeil and P. Hugenholtz, *Nat. Biotechnol.*, 2018, **36**, 996–1004.
- 27 B. R. Terlouw, K. Blin, J. C. Navarro-Munoz, N. E. Avalon, M. G. Chevrette, S. Egbert, S. Lee, D. Meijer, M. J. J. Recchia, Z. L. Reitz, J. A. van Santen, N. Selem-Mojica, T. Torring, L. Zaroubi, M. Alanjary, G. Aleti, C. Aguilar, S. A. A. Al-Salihi, H. E. Augustijn, J. A. Avelar-Rivas, L. A. Avitia-Dominguez, F. Barona-Gomez, J. Bernaldo-Aguero, V. A. Bielinski, F. Biermann, T. J. Booth, V. J. Carrion Bravo, R. Castelo-Branco, F. O. Chagas, P. Cruz-Morales, C. Du, K. R. Duncan, A. Gavriilidou, D. Gayraud, K. Gutierrez-Garcia, K. Haslinger, E. J. N. Helfrich, J. J. J. van der Hooft,



- A. P. Jati, E. Kalkreuter, N. Kalyvas, K. B. Kang, S. Kautsar, W. Kim, A. M. Kunjapur, Y. X. Li, G. M. Lin, C. Loureiro, J. J. R. Louwen, N. L. L. Louwen, G. Lund, J. Parra, B. Philmus, B. Pourmohsenin, L. J. U. Pronk, A. Rego, D. A. B. Rex, S. Robinson, L. R. Rosas-Becerra, E. T. Roxborough, M. A. Schorn, D. J. Scobie, K. S. Singh, N. Sokolova, X. Tang, D. Udway, A. Vigneshwari, K. Vind, S. Vromans, V. Waschulin, S. E. Williams, J. M. Winter, T. E. Witte, H. Xie, D. Yang, J. Yu, M. Zdouc, Z. Zhong, J. Collemare, R. G. Linington, T. Weber and M. H. Medema, *Nucleic Acids Res.*, 2023, **51**, D603–D610.
- 28 O. Strunecky, A. P. Ivanova and J. Mares, *J. Phycol.*, 2023, **59**, 12–51.
- 29 P. Rajaniemi, P. Hrouzek, K. Kastovska, R. Willame, A. Rantala, L. Hoffmann, J. Komarek and K. Sivonen, *Int. J. Syst. Evol. Microbiol.*, 2005, **55**, 11–26.
- 30 J. Osterholm, R. V. Popin, D. P. Fewer and K. Sivonen, *Toxins*, 2020, **12**, 248.
- 31 N. Engene, E. C. Rottacker, J. Kastovsky, T. Byrum, H. Choi, M. H. Ellisman, J. Komarek and W. H. Gerwick, *Int. J. Syst. Evol. Microbiol.*, 2012, **62**, 1171–1178.
- 32 A. E. Tronholm and N. Engene, *Not. algarum*, 2019, **122**, 1–2.
- 33 S. Suda, M. M. Watanabe, S. Otsuka, A. Mahakahant, W. Yongmanitchai, N. Nopartnaraporn, Y. Liu and J. G. Day, *Int. J. Syst. Evol. Microbiol.*, 2002, **52**, 1577–1595.
- 34 A. Oren, *Int. J. Syst. Evol. Microbiol.*, 2011, **61**, 10–15.
- 35 R. L. Burnap, *Front. Bioeng. Biotechnol.*, 2015, **3**, 1.
- 36 R. Rippka, *Methods Enzymol.*, 1988, **167**, 3–27.
- 37 D. O. Alvarenga, M. F. Fiore and A. M. Varani, *Front. Microbiol.*, 2017, **8**, 809.
- 38 K. Heck, G. S. Machineski, D. O. Alvarenga, M. Vaz, A. M. Varani and M. F. Fiore, *J. Microbiol. Methods*, 2016, **129**, 55–60.
- 39 B. M. Berla, R. Saha, C. M. Immethun, C. D. Maranas, T. S. Moon and H. B. Pakrasi, *Front. Microbiol.*, 2013, **4**, 246.
- 40 J. Yu, M. Liberton, P. F. Cliften, R. D. Head, J. M. Jacobs, R. D. Smith, D. W. Koppenaal, J. J. Brand and H. B. Pakrasi, *Sci. Rep.*, 2015, **5**, 8132.
- 41 D. H. Baracho and A. T. Lombardi, *Microb. Cell Fact.*, 2023, **22**, 36.
- 42 L. Bahr, A. Wustenberg and R. Ehwald, *J. Appl. Phycol.*, 2016, **28**, 783–793.
- 43 A. Guljamow, M. Kreische, K. Ishida, A. Liaimer, B. Altermark, L. Bahr, C. Hertweck, R. Ehwald and E. Dittmann, *Appl. Environ. Microbiol.*, 2017, **83**, e01510–e01517.
- 44 I. Echenique-Subiabre, A. Villeneuve, S. Golubic, J. Turquet, J. F. Humbert and M. Gugger, *Microb. Ecol.*, 2015, **69**, 234–244.
- 45 S. Elkobi-Peer and S. Carmeli, *Mar. Drugs*, 2015, **13**, 2347–2375.
- 46 L. A. Salvador, J. S. Biggs, V. J. Paul and H. Luesch, *J. Nat. Prod.*, 2011, **74**, 917–927.
- 47 K. A. Berg, C. Lyra, K. Sivonen, L. Paulin, S. Suomalainen, P. Tuomi and J. Rapala, *ISME J.*, 2009, **3**, 314–325.
- 48 C. Zuniga, T. Li, M. T. Guarnieri, J. P. Jenkins, C. T. Li, K. Bingol, Y. M. Kim, M. J. Betenbaugh and K. Zengler, *Nat. Commun.*, 2020, **11**, 3803.
- 49 B. W. Jester, H. Zhao, M. Gewe, T. Adame, L. Perruzza, D. T. Bolick, J. Agosti, N. Khuong, R. Kuestner, C. Gamble, K. Cruickshank, J. Ferrara, R. Lim, T. Paddock, C. Brady, S. Ertel, M. Zhang, A. Pollock, J. Lee, J. Xiong, M. Tasch, T. Saveria, D. Doughty, J. Marshall, D. Carrieri, L. Goetsch, J. Dang, N. Sanjaya, D. Fletcher, A. Martinez, B. Kadis, K. Sigmar, E. Afreen, T. Nguyen, A. Randolph, A. Taber, A. Krzeszowski, B. Robinett, D. B. Volkin, F. Grassi, R. Guerrant, R. Takeuchi, B. Finrow, C. Behnke and J. Roberts, *Nat. Biotechnol.*, 2022, **40**, 956–964.
- 50 B. E. Rubin, S. Diamond, B. F. Cress, A. Crits-Christoph, Y. C. Lou, A. L. Borges, H. Shivram, C. He, M. Xu, Z. Zhou, S. J. Smith, R. Rovinsky, D. C. J. Smock, K. Tang, T. K. Owens, N. Krishnappa, R. Sachdeva, R. Barrangou, A. M. Deutschbauer, J. F. Banfield and J. A. Doudna, *Nat. Microbiol.*, 2022, **7**, 34–47.
- 51 C. Pancrace, K. Ishida, E. Briand, D. G. Pichi, A. R. Weiz, A. Guljamow, T. Scalvenzi, N. Sassoon, C. Hertweck, E. Dittmann and M. Gugger, *ACS Chem. Biol.*, 2019, **14**, 67–75.
- 52 G. C. A. Amos, T. Awakawa, R. N. Tuttle, A. C. Letzel, M. C. Kim, Y. Kudo, W. Fenical, B. S. Moore and P. R. Jensen, *Proc. Natl. Acad. Sci. U. S. A.*, 2017, **114**, E11121–E11130.
- 53 D. Dehm, J. Krumbholz, M. Baunach, V. Wiebach, K. Hinrichs, A. Guljamow, T. Tabuchi, H. Jenke-Kodama, R. D. Sussmuth and E. Dittmann, *ACS Chem. Biol.*, 2019, **14**, 1271–1279.
- 54 H. Wei, Z. Lin, D. Li, Q. Gu and T. Zhu, *Weishengwu Xuebao*, 2010, **50**, 701–709.
- 55 D. Dhakal, M. Chen, H. Luesch and Y. Ding, *J. Ind. Microbiol. Biotechnol.*, 2021, **48**, kuab003.
- 56 J. J. R. Louwen and J. J. J. van der Hooft, *mSystems*, 2021, **6**, e0072621.
- 57 N. Ziemert, M. Alanjary and T. Weber, *Nat. Prod. Rep.*, 2016, **33**, 988–1005.
- 58 L. K. Caesar, R. Montaser, N. P. Keller and N. L. Kelleher, *Nat. Prod. Rep.*, 2021, **38**, 2041–2065.
- 59 T. Hautbergue, E. L. Jamin, L. Debrauwer, O. Puel and I. P. Oswald, *Nat. Prod. Rep.*, 2018, **35**, 147–173.
- 60 J. J. J. van der Hooft, H. Mohimani, A. Bauermeister, P. C. Dorrestein, K. R. Duncan and M. H. Medema, *Chem. Soc. Rev.*, 2020, **49**, 3297–3314.
- 61 J. A. van Santen, S. A. Kautsar, M. H. Medema and R. G. Linington, *Nat. Prod. Rep.*, 2021, **38**, 264–278.
- 62 M. R. Jones, E. Pinto, M. A. Torres, F. Dorr, H. Mazur-Marzec, K. Szubert, L. Tartaglione, C. Dell'Aversano, C. O. Miles, D. G. Beach, P. McCarron, K. Sivonen, D. P. Fewer, J. Jokela and E. M. Janssen, *Water Res.*, 2021, **196**, 117017.
- 63 A. Rutz, M. Sorokina, J. Galgonek, D. Mietchen, E. Willighagen, A. Gaudry, J. G. Graham, R. Stephan, R. Page, J. Vondrasek, C. Steinbeck, G. F. Pauli,



- J. L. Wolfender, J. Bisson and P. M. Allard, *Elife*, 2022, **11**, e70780.
- 64 M. A. Schorn, S. Verhoeven, L. Ridder, F. Huber, D. D. Acharya, A. A. Aksenov, G. Aleti, J. A. Moghaddam, A. T. Aron, S. Aziz, A. Bauermeister, K. D. Bauman, M. Baunach, C. Beemelmans, J. M. Beman, M. V. Berlanga-Clavero, A. A. Blacutt, H. B. Bode, A. Boullie, A. Brejnrod, T. S. Bugni, A. Calteau, L. Cao, V. J. Carrion, R. Castelo-Branco, S. Chanana, A. B. Chase, M. G. Chevrette, L. V. Costa-Lotufu, J. M. Crawford, C. R. Currie, B. Cuyppers, T. Dang, T. de Rond, A. M. Demko, E. Dittmann, C. Du, C. Drozd, J. C. Dujardin, R. J. Dutton, A. Edlund, D. P. Fewer, N. Garg, J. M. Gauglitz, E. C. Gentry, L. Gerwick, E. Glukhov, H. Gross, M. Gugger, D. G. Guillen Matus, E. J. N. Helfrich, B. F. Hempel, J. S. Hur, M. Iorio, P. R. Jensen, K. B. Kang, L. Kaysser, N. L. Kelleher, C. S. Kim, K. H. Kim, I. Koester, G. M. Konig, T. Leao, S. R. Lee, Y. Y. Lee, X. Li, J. C. Little, K. N. Maloney, D. Mannle, H. C. Martin, A. C. McAvoy, W. W. Metcalf, H. Mohimani, C. Molina-Santiago, B. S. Moore, M. W. Mullowney, M. Muskat, L. F. Nothias, E. C. O'Neill, E. I. Parkinson, D. Petras, J. Piel, E. C. Pierce, K. Pires, R. Reher, D. Romero, M. C. Roper, M. Rust, H. Saad, C. Saenz, L. M. Sanchez, S. J. Sorensen, M. Sosio, R. D. Sussmuth, D. Sweeney, K. Tahlan, R. J. Thomson, N. J. Tobias, A. E. Trindade-Silva, G. P. van Wezel, M. Wang, K. C. Weldon, F. Zhang, N. Ziemert, K. R. Duncan, M. Crusemann, S. Rogers, P. C. Dorrestein, M. H. Medema and J. J. J. van der Hooft, *Nat. Chem. Biol.*, 2021, **17**, 363–368.
- 65 N. Leikoski, L. Liu, J. Jokela, M. Wahlsten, M. Gugger, A. Calteau, P. Permi, C. A. Kerfeld, K. Sivonen and D. P. Fewer, *Chem. Biol.*, 2013, **20**, 1033–1043.
- 66 A. T. Aron, E. C. Gentry, K. L. McPhail, L. F. Nothias, M. Nothias-Esposito, A. Bouslimani, D. Petras, J. M. Gauglitz, N. Sikora, F. Vargas, J. J. J. van der Hooft, M. Ernst, K. B. Kang, C. M. Aceves, A. M. Caraballo-Rodriguez, I. Koester, K. C. Weldon, S. Bertrand, C. Roullier, K. Sun, R. M. Tehan, P. C. Boya, M. H. Christian, M. Gutierrez, A. M. Ulloa, J. A. Tejada Mora, R. Mojica-Flores, J. Lakey-Beitia, V. Vasquez-Chaves, Y. Zhang, A. I. Calderon, N. Tayler, R. A. Keyzers, F. Tugizimana, N. Ndlovu, A. A. Aksenov, A. K. Jarmusch, R. Schmid, A. W. Truman, N. Bandeira, M. Wang and P. C. Dorrestein, *Nat. Protoc.*, 2020, **15**, 1954–1991.
- 67 R. Schmid, D. Petras, L. F. Nothias, M. Wang, A. T. Aron, A. Jagels, H. Tsugawa, J. Rainer, M. Garcia-Aloy, K. Duhrkop, A. Korf, T. Pluskal, Z. Kamenik, A. K. Jarmusch, A. M. Caraballo-Rodriguez, K. C. Weldon, M. Nothias-Esposito, A. A. Aksenov, A. Bauermeister, A. Albarracin Orio, C. O. Grundmann, F. Vargas, I. Koester, J. M. Gauglitz, E. C. Gentry, Y. Hovelmann, S. A. Kalinina, M. A. Pendergraft, M. Panitchpakdi, R. Tehan, A. Le Gouellec, G. Aleti, H. Mannocho Russo, B. Arndt, F. Hubner, H. Hayen, H. Zhi, M. Raffatellu, K. A. Prather, L. I. Aluwihare, S. Bocker, K. L. McPhail, H. U. Humpf, U. Karst and P. C. Dorrestein, *Nat. Commun.*, 2021, **12**, 3832.
- 68 K. Kleigrew, J. Almaliti, I. Y. Tian, R. B. Kinnel, A. Korobeynikov, E. A. Monroe, B. M. Duggan, V. Di Marzo, D. H. Sherman, P. C. Dorrestein, L. Gerwick and W. H. Gerwick, *J. Nat. Prod.*, 2015, **78**, 1671–1682.
- 69 T. Pluskal, S. Castillo, A. Villar-Briones and M. Orešič, MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data, *BMC Bioinformatics*, 2010, **11**, 395.
- 70 S. A. C. Figueiredo, M. Preto, G. Moreira, T. P. Martins, K. Abt, A. Melo, V. M. Vasconcelos and P. N. Leao, *Angew Chem. Int. Ed. Engl.*, 2021, **60**, 10064–10072.
- 71 D. S. May, C. M. Crnkovic, A. Kronic, T. A. Wilson, J. R. Fuchs and J. E. Orjala, *ACS Chem. Biol.*, 2020, **15**, 758–765.
- 72 T. Leao, M. Wang, N. Moss, R. da Silva, J. Sanders, S. Nurk, A. Gurevich, G. Humphrey, R. Reher, Q. Zhu, P. Belda-Ferre, E. Glukhov, S. Whitner, K. L. Alexander, R. Rex, P. Pevzner, P. C. Dorrestein, R. Knight, N. Bandeira, W. H. Gerwick and L. Gerwick, *Mar. Drugs*, 2021, **19**, 20.
- 73 J. C. Navarro-Munoz, N. Selem-Mojica, M. W. Mullowney, S. A. Kautsar, J. H. Tryon, E. I. Parkinson, E. L. C. De Los Santos, M. Yeong, P. Cruz-Morales, S. Abubucker, A. Roeters, W. Lokhorst, A. Fernandez-Guerra, L. T. D. Cappelini, A. W. Goering, R. J. Thomson, W. W. Metcalf, N. L. Kelleher, F. Barona-Gomez and M. H. Medema, *Nat. Chem. Biol.*, 2020, **16**, 60–68.
- 74 R. R. da Silva, M. Wang, L. F. Nothias, J. J. J. van der Hooft, A. M. Caraballo-Rodriguez, E. Fox, M. J. Balunas, J. L. Klassen, N. P. Lopes and P. C. Dorrestein, *PLoS Comput. Biol.*, 2018, **14**, e1006089.
- 75 H. Mohimani, A. Gurevich, A. Shlemov, A. Mikheenko, A. Korobeynikov, L. Cao, E. Shcherbin, L. F. Nothias, P. C. Dorrestein and P. A. Pevzner, *Nat. Commun.*, 2018, **9**, 4035.
- 76 M. Ernst, K. B. Kang, A. M. Caraballo-Rodriguez, L. F. Nothias, J. Wandy, C. Chen, M. Wang, S. Rogers, M. H. Medema, P. C. Dorrestein and J. J. J. van der Hooft, *Metabolites*, 2019, **9**, 144.
- 77 H. Mohimani, W. T. Liu, R. D. Kersten, B. S. Moore, P. C. Dorrestein and P. A. Pevzner, *J. Nat. Prod.*, 2014, **77**, 1902–1909.
- 78 L. Cao, A. Gurevich, K. L. Alexander, C. B. Naman, T. Leao, E. Glukhov, T. Luzzatto-Knaan, F. Vargas, R. Quinn, A. Bouslimani, L. F. Nothias, N. K. Singh, J. G. Sanders, R. A. S. Benitez, L. R. Thompson, M. N. Hamid, J. T. Morton, A. Mikheenko, A. Shlemov, A. Korobeynikov, I. Friedberg, R. Knight, K. Venkateswaran, W. H. Gerwick, L. Gerwick, P. C. Dorrestein, P. A. Pevzner and H. Mohimani, *Cell Syst.*, 2019, **9**, 600–608.
- 79 N. J. Merwin, W. K. Mousa, C. A. Dejong, M. A. Skinnider, M. J. Cannon, H. Li, K. Dial, M. Gunabalasingam, C. Johnston and N. A. Magarvey, *Proc. Natl. Acad. Sci. U. S. A.*, 2020, **117**, 371–380.
- 80 L. K. Caesar, F. A. Butun, M. T. Robey, N. J. Ayon, R. Gupta, D. Daiko, J. W. Bok, G. Nickles, R. J. Stankey, D. Johnson,



- D. Mead, K. B. Cank, C. E. Earp, H. A. Raja, N. H. Oberlies, N. P. Keller and N. L. Kelleher, *Nat. Chem. Biol.*, 2023, **19**, 846–854.
- 81 G. Hjorleifsson Eldjarn, A. Ramsay, J. J. J. van der Hooft, K. R. Duncan, S. Soldatou, J. Rousu, R. Daly, J. Wandy and S. Rogers, *PLoS Comput. Biol.*, 2021, **17**, e1008920.
- 82 S. Romano, S. A. Jackson, S. Patry and A. D. W. Dobson, *Mar. Drugs*, 2018, **16**, 244.
- 83 E. Arstol and M. F. Hohmann-Marriott, *Mar. Drugs*, 2019, **17**, 281.
- 84 T. Galica, N. Borbone, J. Mares, A. Kust, A. Caso, G. Esposito, K. Saurav, J. Hajek, K. Rehakova, P. Urajova, V. Costantino and P. Hrouzek, *Appl. Environ. Microbiol.*, 2021, **87**, e0312820.
- 85 S. Breinlinger, T. J. Phillips, B. N. Haram, J. Mares, J. A. Martinez Yerena, P. Hrouzek, R. Sobotka, W. M. Henderson, P. Schmieder, S. M. Williams, J. D. Lauderdale, H. D. Wilde, W. Gerrin, A. Kust, J. W. Washington, C. Wagner, B. Geier, M. Liebeke, H. Enke, T. H. J. Niedermeyer and S. B. Wilde, *Science*, 2021, **371**, eaax9050.
- 86 Q. Gao and F. Garcia-Pichel, *Nat. Rev. Microbiol.*, 2011, **9**, 791–802.
- 87 T. Soule, V. Stout, W. D. Swingley, J. C. Meeks and F. Garcia-Pichel, *J. Bacteriol.*, 2007, **189**, 4465–4472.
- 88 C. Hu, G. Voller, R. Sussmuth, E. Dittmann and J. C. Kehr, *Environ. Microbiol.*, 2015, **17**, 1548–1559.
- 89 C. Hu, S. A. Ludsins, J. F. Martin, E. Dittmann and J. Lee, *Harmful Algae*, 2018, **77**, 1–10.
- 90 E. Couradeau, U. Karaoz, H. C. Lim, U. Nunes da Rocha, T. Northen, E. Brodie and F. Garcia-Pichel, *Nat. Commun.*, 2016, **7**, 10373.
- 91 E. Briand, M. Bormans, M. Gugger, P. C. Dorrestein and W. H. Gerwick, *Environ. Microbiol.*, 2016, **18**, 384–400.
- 92 E. Briand, J. F. Humbert, K. Tambosco, M. Bormans and W. H. Gerwick, *Microbiologyopen*, 2016, **5**, 469–478.
- 93 A. Liaimer, E. J. Helfrich, K. Hinrichs, A. Guljamow, K. Ishida, C. Hertweck and E. Dittmann, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **112**, 1862–1867.
- 94 C. Y. Chiang, M. Ohashi and Y. Tang, *Nat. Prod. Rep.*, 2023, **40**, 89–127.
- 95 M. Myronovskiy and A. Luzhetskyy, *Nat. Prod. Rep.*, 2019, **36**, 1281–1294.
- 96 B. C. Covington, F. Xu and M. R. Seyedsayamdost, *Annu. Rev. Biochem.*, 2021, **90**, 763–788.
- 97 E. Dittmann, B. A. Neilan, M. Erhard, H. von Dohren and T. Borner, *Mol. Microbiol.*, 1997, **26**, 779–787.
- 98 K. Ishida, M. Welker, G. Christiansen, S. Cadel-Six, C. Bouchier, E. Dittmann, C. Hertweck and N. Tandeau de Marsac, *Appl. Environ. Microbiol.*, 2009, **75**, 2017–2026.
- 99 T. Nishizawa, A. Ueda, T. Nakano, A. Nishizawa, T. Miura, M. Asayama, K. Fujii, K. Harada and M. Shirai, *J. Biochem.*, 2011, **149**, 475–485.
- 100 L. Rouhiainen, L. Paulin, S. Suomalainen, H. Hyttiainen, W. Buikema, R. Haselkorn and K. Sivonen, *Mol. Microbiol.*, 2000, **37**, 156–167.
- 101 G. Christiansen, J. Fastner, M. Erhard, T. Borner and E. Dittmann, *J. Bacteriol.*, 2003, **185**, 564–572.
- 102 K. Ishida, G. Christiansen, W. Y. Yoshida, R. Kurmayer, M. Welker, N. Valls, J. Bonjoch, C. Hertweck, T. Borner, T. Hemscheidt and E. Dittmann, *Chem. Biol.*, 2007, **14**, 565–576.
- 103 A. Liaimer, H. Jenke-Kodama, K. Ishida, K. Hinrichs, J. Stangeland, C. Hertweck and E. Dittmann, *Environ. Microbiol. Rep.*, 2011, **3**, 550–558.
- 104 T. Barchewitz, A. Guljamow, S. Meissner, S. Timm, M. Henneberg, O. Baumann, M. Hagemann and E. Dittmann, *Environ. Microbiol.*, 2019, **21**, 4836–4851.
- 105 S. Repka, M. Koivula, V. Harjunpa, L. Rouhiainen and K. Sivonen, *Appl. Environ. Microbiol.*, 2004, **70**, 4551–4560.
- 106 J. Krumbholz, K. Ishida, M. Baunach, J. E. Teikari, M. M. Rose, S. Sasso, C. Hertweck and E. Dittmann, *Angew Chem. Int. Ed. Engl.*, 2022, **61**, e202204545.
- 107 E. Bode, A. K. Heinrich, M. Hirschmann, D. Abebew, Y. N. Shi, T. D. Vo, F. Wesche, Y. M. Shi, P. Grun, S. Simonyi, N. Keller, Y. Engel, S. Wenski, R. Bennet, S. Beyer, I. Bischoff, A. Buaya, S. Brandt, I. Cakmak, H. Cimen, S. Eckstein, D. Frank, R. Furst, M. Gand, G. Geisslinger, S. Hazir, M. Henke, R. Heermann, V. Lecaudey, W. Schafer, S. Schiffmann, A. Schuffler, R. Schwenk, M. Skaljic, E. Thines, M. Thines, T. Ulshofer, A. Vilcinskas, T. A. Wichelhaus and H. B. Bode, *Angew Chem. Int. Ed. Engl.*, 2019, **58**, 18957–18963.
- 108 S. H. Park, K. Lee, J. W. Jang and J. S. Hahn, *ACS Synth. Biol.*, 2019, **8**, 346–357.
- 109 E. J. Kim, J. H. Lee, H. Choi, A. R. Pereira, Y. H. Ban, Y. J. Yoo, E. Kim, J. W. Park, D. H. Sherman, W. H. Gerwick and Y. J. Yoon, *Org. Lett.*, 2012, **14**, 5824–5827.
- 110 J. J. Zhang, X. Tang and B. S. Moore, *Nat. Prod. Rep.*, 2019, **36**, 1313–1332.
- 111 M. S. Donia, B. J. Hathaway, S. Sudek, M. G. Haygood, M. J. Rosovitz, J. Ravel and E. W. Schmidt, *Nat. Chem. Biol.*, 2006, **2**, 729–735.
- 112 M. S. Donia, J. Ravel and E. W. Schmidt, *Nat. Chem. Biol.*, 2008, **4**, 341–343.
- 113 N. Leikoski, D. P. Fewer, J. Jokela, M. Wahlsten, L. Rouhiainen and K. Sivonen, *Appl. Environ. Microbiol.*, 2010, **76**, 701–709.
- 114 P. F. Long, W. C. Dunlap, C. N. Battershill and M. Jaspars, *ChemBioChem*, 2005, **6**, 1760–1765.
- 115 E. W. Schmidt, J. T. Nelson, D. A. Rasko, S. Sudek, J. A. Eisen, M. G. Haygood and J. Ravel, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 7315–7320.
- 116 W. Tang and W. A. van der Donk, *Biochemistry*, 2012, **51**, 4271–4279.
- 117 A. R. Weiz, K. Ishida, K. Makower, N. Ziemert, C. Hertweck and E. Dittmann, *Chem. Biol.*, 2011, **18**, 1413–1421.
- 118 N. Ziemert, K. Ishida, A. Liaimer, C. Hertweck and E. Dittmann, *Angew Chem. Int. Ed. Engl.*, 2008, **47**, 7756–7759.
- 119 D. Liu and H. B. Pakrasi, *Microb. Cell Fact.*, 2018, **17**, 48.



- 120 T. Liu, R. Mazmouz, S. E. Ongley, R. Chau, R. Pickford, J. N. Woodhouse and B. A. Neilan, *ACS Chem. Biol.*, 2017, **12**, 2021–2029.
- 121 K. N. Wells, P. Videau, D. Nelson, J. E. Eiting and B. Philmus, *FEMS Microbiol. Lett.*, 2018, **365**, fny164.
- 122 R. H. Lambalot, A. M. Gehring, R. S. Flugel, P. Zuber, M. LaCelle, M. A. Marahiel, R. Reid, C. Khosla and C. T. Walsh, *Chem. Biol.*, 1996, **3**, 923–936.
- 123 G. Yang, Y. Zhang, N. K. Lee, M. A. Cozad, S. E. Kearney, H. Luesch and Y. Ding, *Sci. Rep.*, 2017, **7**, 11888.
- 124 P. M. D'Agostino, C. J. Seel, X. Ji, T. Gulder and T. A. M. Gulder, *Nat. Chem. Biol.*, 2022, **18**, 652–658.
- 125 N. Eusebio, R. Castelo-Branco, D. Sousa, M. Preto, P. D'Agostino, T. A. M. Gulder and P. N. Leao, *ACS Synth. Biol.*, 2022, **11**, 3493–3503.
- 126 C. Greunke, E. R. Duell, P. M. D'Agostino, A. Glockle, K. Lamm and T. A. M. Gulder, *Metab. Eng.*, 2018, **47**, 334–345.
- 127 P. Videau, K. N. Wells, A. J. Singh, J. Eiting, P. J. Proteau and B. Philmus, *ACS Synth. Biol.*, 2020, **9**, 63–75.
- 128 P. Videau, K. N. Wells, A. J. Singh, W. H. Gerwick and B. Philmus, *ACS Synth. Biol.*, 2016, **5**, 978–988.
- 129 H. Zhang, L. Fang, M. S. Osburne and B. A. Pfeifer, *Methods Mol. Biol.*, 2016, **1401**, 121–134.
- 130 S. E. Ongley, X. Bian, Y. Zhang, R. Chau, W. H. Gerwick, R. Muller and B. A. Neilan, *ACS Chem. Biol.*, 2013, **8**, 1888–1893.
- 131 T. Liu, R. Mazmouz, L. A. Pearson and B. A. Neilan, *ACS Synth. Biol.*, 2019, **8**, 1187–1194.
- 132 P. M. D'Agostino and T. A. M. Gulder, *ACS Synth. Biol.*, 2018, **7**, 1702–1708.
- 133 J. H. Cardellina 2nd, F. J. Marner and R. E. Moore, *Science*, 1979, **204**, 193–195.
- 134 A. C. Jones, S. Otilie, A. S. Eustaquio, D. J. Edwards, L. Gerwick, B. S. Moore and W. H. Gerwick, *FEBS J.*, 2012, **279**, 1243–1251.
- 135 G. Yang, M. A. Cozad, D. A. Holland, Y. Zhang, H. Luesch and Y. Ding, *ACS Synth. Biol.*, 2018, **7**, 664–671.
- 136 V. Agarwal, J. M. Blanton, S. Podell, A. Taton, M. A. Schorn, J. Busch, Z. Lin, E. W. Schmidt, P. R. Jensen, V. J. Paul, J. S. Biggs, J. W. Golden, E. E. Allen and B. S. Moore, *Nat. Chem. Biol.*, 2017, **13**, 537–543.
- 137 S. Baldanta, G. Guevara and J. M. Navarro-Llorens, *Microb. Cell Fact.*, 2022, **21**, 103.
- 138 B. Bishe, A. Taton and J. W. Golden, *iScience*, 2019, **20**, 216–228.
- 139 T. C. Niu, G. M. Lin, L. R. Xie, Z. Q. Wang, W. Y. Xing, J. Y. Zhang and C. C. Zhang, *ACS Synth. Biol.*, 2019, **8**, 170–180.
- 140 J. Svoboda, B. Cisneros and B. Philmus, *Synth. Biol.*, 2021, **6**, ysab019.
- 141 D. Back, T. J. O'Donnell, K. K. Axt, J. R. Gurr, J. M. Vanegas, P. G. Williams and B. Philmus, *ACS Chem. Biol.*, 2023, **18**, 1797–1807.
- 142 A. Taton, A. Ecker, B. Diaz, N. A. Moss, B. Anderson, R. Reher, T. F. Leao, R. Simkovsky, P. C. Dorrestein, L. Gerwick, W. H. Gerwick and J. W. Golden, *ACS Synth. Biol.*, 2020, **9**, 3364–3376.
- 143 A. Taton, S. Rohrer, B. Diaz, R. Reher, A. M. Caraballo Rodriguez, M. L. Pierce, P. C. Dorrestein, L. Gerwick, W. H. Gerwick and J. W. Golden, *ACS Chem. Biol.*, 2022, **17**, 1910–1923.
- 144 E. S. Sattely, M. A. Fischbach and C. T. Walsh, *Nat. Prod. Rep.*, 2008, **25**, 757–793.
- 145 R. A. Sheldon and J. M. Woodley, *Chem. Rev.*, 2018, **118**, 801–838.
- 146 S. Adak, A. L. Lukowski, R. J. B. Schäfer and B. S. Moore, *J. Am. Chem. Soc.*, 2022, **144**, 2861–2866.
- 147 S. T. Lima, T. R. Fallon, J. L. Cordoza, J. R. Chekan, E. Delbaje, A. R. Hopenavouri, D. O. Alvarenga, S. M. Wood, H. Luhavaya, J. T. Baumgartner, F. A. Dörr, A. Etchegaray, E. Pinto, S. M. K. McKinnie, M. F. Fiore and B. S. Moore, *J. Am. Chem. Soc.*, 2022, **144**, 9372–9379.
- 148 C. P. Mason, K. R. Edwards, R. E. Carlson, J. Pignatello, F. K. Gleason and J. M. Wood, *Science*, 1982, **215**, 400–402.
- 149 X. Yang, Y. Shimizu, J. R. Steiner and J. Clardy, *Tetrahedron Lett.*, 1993, **34**, 761–764.
- 150 S. C. Lee and G. D. Brown, *J. Nat. Prod.*, 1998, **61**, 29–33.
- 151 S. Sarkar, W. Gu and E. W. Schmidt, *ACS Catal.*, 2020, **10**, 7146–7153.
- 152 A. Colombano, L. Dalponte, S. Dall'Angelo, C. Clemente, M. Idress, A. Ghazal and W. E. Houssen, *Angew Chem. Int. Ed. Engl.*, 2023, **62**, e202215979.
- 153 B. Choi and A. J. Link, *Trends Chem.*, 2023, **5**, 620–633.
- 154 T. J. Oman, P. J. Knerr, N. A. Bindman, J. E. Velásquez and W. A. van der Donk, *J. Am. Chem. Soc.*, 2012, **134**, 6952–6955.
- 155 E. Reyna-González, B. Schmid, D. Petras, R. D. Süßmuth and E. Dittmann, *Angew Chem. Int. Ed. Engl.*, 2016, **55**, 9398–9401.
- 156 M. N. Ahmed, E. Reyna-González, B. Schmid, V. Wiebach, R. D. Süßmuth, E. Dittmann and D. P. Fewer, *ACS Chem. Biol.*, 2017, **12**, 1538–1546.
- 157 S. Scholz, S. Kerestetzopoulou, V. Wiebach, R. Schnegotzki, B. Schmid, E. Reyna-González, L. Ding, R. D. Süßmuth, E. Dittmann and M. Baunach, *ChemBioChem*, 2022, **23**, e202200345.
- 158 B. I. Morinaka, E. Lakis, M. Verest, M. J. Helf, T. Scalvenzi, A. L. Vagstad, J. Sims, S. Sunagawa, M. Gugger and J. Piel, *Science*, 2018, **359**, 779–782.
- 159 E. Lakis, S. Magyari and J. Piel, *Angew Chem. Int. Ed. Engl.*, 2022, **61**, e202202695.
- 160 D. Richter, E. Lakis and J. Piel, *Nat. Chem.*, 2023, 1422–1430.
- 161 H. Nakamura, E. E. Schultz and E. P. Balskus, *Nat. Chem. Biol.*, 2017, **13**, 916–921.
- 162 N. R. Braffman, T. B. Ruskoski, K. M. Davis, N. R. Glasser, C. Johnson, C. D. Okafor, A. K. Boal and E. P. Balskus, *eLife*, 2022, **11**, e75761.

